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 Fibronectin polymerized and assembled into globules on the surface of breast 
cancer cells has been shown to mediate metastasis to the lungs. Disruption of the 
binding between these tumor-cell surface-associated fibronectin, or polymeric 
fibronectin (polyFn), and dipeptidyl peptidase (DPPIV) negatively impacts breast 
cancer lung colonization. This dissertation was designed to characterize the molecular 
mechanisms underlying assembly of surface coated polyFn to understand the 
regulation of breast cancer cell surface polyFn. 
 In order to investigate the signaling pathways involved in polyFn assembly, we 
utilized pharmacological inhibitors for various signaling pathways that have been 
proposed to regulate cellular function. Mutant plasmid expression, siRNA knockdown 
of proteins and biochemical analyses were carried out to identify the particular kinase 
involved in regulating polyFn. The ability of rat breast cancer cells to assemble polyFn 
was impaired by disruption of PKCε function. Knockdown of fibronectin also 
abolished polyFn formation. Cells with knockdown of either PKCε or fibronectin both 
had diminished ability to colonize the lungs in rat tail vein injection metastasis model. 
 To further substantiate the role of PKCε in lung metastasis-mediating polyFn, 
mass spectrometry analysis was performed on the PKCε complex. Two proteins were 
identified and tested with corresponding inhibitors to relate cellular function to polyFn 
assembly. Detailed biochemical analyses, immunofluorescent microscopy, mutant 
protein expression and pharmacological inhibition demonstrated that the subcellular 
localization of PKCε complex with actin cytoskeleton has a great impact on polyFn 
assembly. A focal adhesion kinase was also identified to be involved. Therefore, 
PKCε exhibits its effects on polyFn by controlling the activation of downstream 
signaling proteins. 
 In summary, the presence of endogenous cellular fibronectin and catalytically 
competent PKCε is a prerequisite of successful polyFn assembly. Proper subcellular 
localization of PKCε-actin complex facilitates PKCε downstream signaling, most 
likely to Pyk2, promoting the formation of polyFn surface formation. These results 
present a novel potential signaling pathway for therapeutical intervention in breast 
cancer metastasis.  
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CHAPTER I 
 
FIBRONECTIN IN CANCER PROGRESSION AND METASTASIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
INTRODUCTION 
 
The extracellular matrix (ECM) supports specific interactions with cell surface 
receptors and is essential for tissue function. Fibronectin (Fn), an abundant ECM 
glycoprotein, is involved in a variety of cellular functions and disease processes. Fn 
regulates cellular functions such as cell adhesion, cell migration and cell proliferation. 
Fn is necessary for proper embryonic development and tissue repair and disregulation 
of Fn leads to diseases of the skin, liver, lung, cartilage and bones as well as cancer 
progression. The integral role of Fn in maintenance of normal cell function cannot be 
undermined. In this review, we will take a look at the structure and domains of Fn, 
consequences of Fn deletion, Fn matrix assembly and provide a brief overview of Fn 
function in cancer progression and metastasis. 
 
STRUCTURE OF FIBRONECTIN 
 
 Fibronectin (Fn) is a glycoprotein that exists as a dimer comprised of two 220-
250 kDa subunits connected at the C-termini by disulfide bonds (1,2) (Fig 1.1). Each 
subunit consists of repeating modules (Fn repeats) that includes type I, type II and 
type III repeats. Type I repeats contain two disulfide bonds and contain approximately 
40 amino acids; type II repeats are about 60 amino-acid residues in length and 
contains two intrachain disulfide bonds; and type II repeats are 90 residues in length 
and have no disulfide bonds. Fn is comprised of 12 type I repeats, 2 type II repeats, 
15-17 type III repeats and a variable(V) region not homologous to other areas on Fn 
(1,2). These domains contain multiple binding sites for heparin and for various cell 
surface receptors that modulate cellular function.  
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Magnusson, M. K. et al. (1998) Arterioscler Thromb Vasc Biol 18(9), 1363-1370 
Figure 1.1: Schematic diagram of modular structure of Fn dimer (2). 
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The 2 type II repeats that undergo alternative splicing are termed EDA (ED, 
extradomain) and EDB (Fig 1.2). Fn can be subdivided into 2 forms based on 
solubility: the more soluble plasma Fn and the less soluble cellular FN. Plasma FN 
(pFn), which is synthesized in hepatocytes, has a simple splicing pattern and contains 
neither EDA nor EDB while cellular Fn (cFn), which is synthesized in tissues, 
contains either or both of EDA and EDB and is a more heterogenous group of Fn 
isoforms as a consequence of cell-type and species-specific alternative splicing (3). In 
pFn, only one of the subunits contains Variable (V) region whereas most cFn contains 
V region (1,2). 
 Individual type III repeats have only 20-40% identity in amino acid sequence 
but a high degree of structural homology. Type III repeats are organized into 7 anti-
parallel β strands with exposed loops within these strands. Fn domains may be 
structurally modified, which can expose cryptic sites induced by mechanical forces 
stretching the Fn molecule, proteolysis, or incorporation of one or both of EDA and 
EDB (4). Exposure of cryptic site allows Fn molecule self association (5) and has a 
potential role in serving as nucleation sites for Fn polymerization and fibril assembly 
(6). 
 
FIBRONECTIN SPLICE VARIANTS AND FUNCTIONS  
 
 Fibronectin was one of the first genes to be reported to be alternatively spliced 
and is one of the best studied models of alternative splicing (4). During transcription, 
the EDA and EDB exons can be included or excluded from Fn mRNA while the V 
region (also called IIICS, type III connecting segment) can be completely 
included(V120), partially included, or excluded(V0), depending on species (4) (Fig 
1.2). On top of alternatively spliced forms, in zebrafish, 2 Fn genes are present (FN1a  
4 
  
White, E. S. et al. (2008) J Pathol 216(1), 1-14 
Figure 1.2: Fibronectin alternative splice sites and sites of integrin receptor and 
cell binding: Splicing of EDA and EDB is similar in all species (total inclusion or 
exclusion) while splicing of the variable region is species specific (4). 
5 
and FN1b) (7). However, the total number of Fn isoforms still correlates with 
evolutionary scale. The 2 independent genes in zebrafish produce only 1 V-region 
variant in FN1a and 2 V variants in FN1b and a total of 5 Fn isoforms (8). In other 
species, frogs and chickens have 2 V variants (generates up to 6 Fn isoforms), rats and 
mice have 3 (produces 12 Fn isoforms) and humans have 5 V variants that generates 
up to 20 Fn isoforms (4).  
 Incorporation of the alternatively spliced region in Fn is increased during 
embryonic development and decreases dramatically after birth and with aging (4,8,9). 
A comparison of fetal and nonfetal fibroblasts shows a loss of EDB inclusion in 
nonfetal cells (10). Analysis of rat embryo mRNA reveals that the entire V region 
(V120) is included in most FN mRNA while rats in later developmental stages contain 
V0, V95 and V120, indicating developmentally regulated splicing (11). RNA from 
mice of different ages after birth up to 24 months revealed the increased inclusion of 
V0 and decreased inclusion of V120 with aging, while V95 showed no change (12). 
Under certain situations, the “embryonic” splicing pattern is re-established in adults, 
such as during tissue repair, tissue fibrosis and angiogenesis. In skin wound healing, 
EDA and EDB are present in the Fn mRNA in the cells at the base of the wound (13). 
During pheripheral nerve regeneration, V25 inclusion was increased while V0 levels 
remain low (14). Cell type specificity of alternative splicing patterns can be seen more 
clearly in adults. In large vessel wall endothelial cells, inclusion of EDA but not EDB 
is seen in Fn. The same EDA+EDB- splice form exists within the uterine 
endometrium. On the other hand, chondrocytes contain EDB+EDA- Fn mRNA (9). 
The differential distribution of different Fn isoforms certainly suggests different roles 
for each of the isoforms in cellular function. 
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 (1) EDA DOMAIN 
 EDA domain has numerous functions which include cell adhesion, wound 
healing, matrix assembly, dimer formation, protein secretion, cell differentiation, 
tissue injury and inflammation, cell cycle progression and various disease processes 
(4). EDA+ Fn is implicated in disease processes such as rheumatoid arthritis (15). A 
low concentration of pFn and EDA-only polypeptide were synergistic for cell 
attachment and spreading and lead to cytoskeletal reorganization and focal contact 
formation compared to either substrate used alone(16). EDA+ Fn was found 
abundantly expressed only in the ECM of scarred human eyes and not normal 
conjunctiva (17), indicating a role in wound healing. In airway epithelial cells that 
secrete Fn from both apical and basal surfaces, EDA+ Fn were only secreted apically, 
demonstrating a role in directing secretion (18). On the other hand, levels of EDA+ Fn 
are elevated in plasma and tissues of patients with certain disorders such as pulmonary 
fibrosis (19), psoriasis, rheumatoid arthritis, diabetes and cancer (4), but the functional 
role of EDA+ Fn has not be clarified. 
  
(2) EDB DOMAIN 
 EDB+ Fn has a positive role in matrix assembly, as it is more efficiently 
incorporated into Fn matrix, along with EDA+ Fn, than EDA-EDB-V-Fn and V+Fn 
(20). Studies on EDB-/- mice revealed no significant phenotype (21-23), but a mild in 
vitro effect on matrix assembly and proliferation (23). EDB-/- embryonic fibroblasts 
grew slower and produced shorter and thinner FN fibrils compared to normal cells 
(23). On the other hand, EDB+ Fn is lost from many cell types upon completion of 
development and its expression correlates closely to cell proliferation (9). Recently, 
EDB+ Fn was found to reside in neoplastic tissue blood vessels but absent from 
mature/adult tissues, highlighting its role in angiogenesis (24). EDB+ Fn may 
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potentiate and assist in vascular development, suggested by the findings that EDB+ Fn 
can increase VEGF expression and endothelial proliferation (24), even though in 
EDB-/- mice a compensatory pathway might exist for angiogenesis. EDB+ Fn is 
upregulated in the serum of diabetic retinopathy patients (25) and is expressed in 
hematologic tumors such as Hodgkin and non-Hodgkin lymphoma (26). Future 
research on these disease models of EDB+ Fn will be able to elucidate the other 
potential cellular functions of this Fn splice variant. 
 
(3) V REGION 
 The V region of Fn contains integrin recognition sites that promote cell 
spreading and migration (9,20). Human Fn contains two cell binding sites within the V 
region: LDV in V25 (CS1) and REDV in V31 (CS5), both sequence are recognized by 
α4β1 integrin. LDV is also found in Xenopus, rat and chicken Fn. REDV is not 
conserved and is RGDV in rat and bovine. The V region mediates tumor invasion, 
motility and spreading of squamous cell carcinoma (27) and hepatocellular carcinoma 
(28). Up regulation of V25 has been shown to enhance nerve repair (29). Increased 
exclusion of the V region has been observed in early disease processes in disease 
models of lupus nephritis and immune complex nephritis (30). In human primary 
fibroblasts, the V region induces apoptosis and concomitant transcriptional decreases 
of c-Myc, p53, p21 and bcl-2 (31). Other roles in Fn secretion and clot formation have 
also been suggested (32).  
 
PHENOTYPES OF FIBRONECTIN KNOCKOUT MICE 
 
 Targeted mutations in the Fn gene in different mouse models have been used 
to complement experimental data by Fn expression. The first Fn-null mice were 
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generated by removing the translation initiation codon and part of the 5’exon to 
disrupt the Fn gene (33). Mice with heterozygous mutation (+/-) are fertile and 
normal, even with only half the normal level of FN (33). However, homozygous 
mutations were embryonic lethal. Fn is not required for blastocyst formation and 
abnormalities in the Fn-null embryos first appear after the onset of gastrulation, which 
includes shortened anterior-posterior axis, mesoderm deficiencies and distorted 
ectoderm. These embryos have an abnormal or no heart, no notochord and no somites 
(33). Heart defects develop depending on genetic background of Fn-null mice: the 
C57/BL6 background developed a less severe heart and blood vessel phenotype in 
which the heart tube forms normally while the 129S4 background is affected earlier in 
development and causes cardia bifida (34). More recently, 5 novel modifier genes 
were identified on chromosome four that were linked to the difference in embryonic 
heart development by comparing the above two genetic backgrounds in mice with 
high throughput SNP genotyping (35). The specific functions of these genes are yet to 
be determined. 
 Fn-null EDB mutations (EDB-cDNA fusion replacement, no introns) produced 
similar embryonic lethal and mesoderm defects as the Fn-null mice (36) while EDB-
null mutation (deletion of EDB exon) created no obvious phenotype in various 
healing, organogenesis, tumorigenesis and thrombosis models (21-23). Conditional 
pFn knockout using ubiquitous Mx-cre recombinase revealed increased neuronal 
apoptosis and brain infarction following cerebral ischemia treatment but no effect on 
wound healing or hemostasis (37). Roles for pFn in thrombosis, angiogenesis and 
bacterial virulence were also suggested in similar pFn knockout models (38-40).  
Deletion of EDA exon produced mice with reduced atherosclerosis but no differences 
in tumor growth or thrombus formation was detected (22,23,41). Mice without the 
EDA exon in the FN protein (EDA-null) and mice having constitutive inclusion of the 
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EDA exon had reduced life spans, while EDA-null mice had wound healing defects 
(42).  Mice engineered with constitutive inclusion of EDA into the FN molecule had 
increased thrombosis and thromboembolism, suggesting a pro-thrombotic role for 
EDA+Fn (43). Roles of EDA+Fn in motor coordination and lung fibrosis were also 
suggested (19,44). 
 On the other hand, double knockout of EDA and EDB was embryonic lethal 
with cardiovascular defects similar but less severe than that of FN-null mice. Deletion 
of both EDA and EDB exons had no effect on protein synthesis, secretion or cell 
surface deposition of Fn, indicating embryonic lethality was due specifically to the 
lack of EIIIA and EIIIB exons from Fn (35). Disruption of the cell binding site RGD 
by mutation to RGE generated was embryonic lethal at E10 (45), suggesting that the 
majority of Fn cellular function is mediated through RGD interaction with integrins. 
Assembly of Fn was normal but embryos had shortened posterior trunk, absent tail 
bud-derived somites and severe vascular defects similar to the phenotype of α5-
integrin deficient mice (45). Although these total knockouts have provide valuable 
clues for Fn function, with newly available technology and well characterized 
promoters, tissue specific Fn deletion models will be able to further dissect the 
specific roles of Fn in various disease models. 
 
CELL-SPECIFIC DELETION OF FIBRONECTIN 
 
 Cell-specific deletion of Fn is used to determine roles of Fn in different organs 
or cell types without the detrimental effects of whole mice Fn knockout. Mice 
engineered to constitutively express EDA+Fn had a significant decrease of Fn levels in 
plasma and most tissues while hepatocytes modified to produce EDA+ Fn have normal 
extracellular matrix Fn levels but secrete less soluble Fn (42). A liver-specific EDA-
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exon deletion in these mice restored Fn levels in both plasma and tissues, indicating 
that a fraction of tissue Fn is plasma derived (46). Future work will be able to reveal 
the other functional significance of Fn in mouse knockout models. 
 
FIBRONECTIN IN MAMMARY GLAND DEVELOPMENT 
 
 The histologic structure of mammary glands varies depending on sex, age and 
physiologic status. The basic mammary gland structure consists of lobules that consist 
of several branching intralobular ducts that end in alveoli (acini). During pregnancy 
and lactation, the mammary gland undergoes striking structural and physiologic 
change, such as acinar growth, as a result of the synergistic action of various 
hormones, which includes estrogen, progesterone, prolactin and human placental 
lactogen (47). Fn levels are regulated by estrogen and progesterone and change 
considerably during mammary gland development, increasing to 3-fold at puberty and 
maintains at high level during pregnancy and lactation (48). Fn is expressed around 
the basal cell surface of acini but downregulated in the late stages of acinar 
morphogenesis (49). A recent paper of mammary cell 3D culture shows that 
fibronectin expression regulates mammary epithelial cell growth. Fn in matrigel 
increases acinar size and Fn supplementation in the medium alters growth arrest state 
of mammary epithelial cells and increases proliferation and luminal filling. 
Dysregulated Fn expression affects proper acinar morphogenesis by altering mammary 
cell proliferative state and prevents lumen formation in mammary gland (49). 
However, proteolytic fragments of Fn suppress growth and promote apoptosis of 
tumorigenic mammary epithelial cells through matrix protease dependent pathways 
(50). ECM proteins like Fn can also influence cell proliferation through regulation of 
integrin interaction with hormones and growth factors. 
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ROLE OF FIBRONECTIN IN BREAST CANCER 
 
The interstitial ECM in normal adult mammary tissue mostly lacks fibronectin 
while increased fibronectin is noted in the stroma of benign mammary hyperplasia and 
various types of mammary tumors and high levels of fibronectin in tissue sections 
correlate with decreased patient survival (49). Subtracted cDNA libraries comparing 
non-breast tissue, normal breast tissue and breast tumors show a threefold expression 
of Fn in breast tumors (51). Gene expression profile of primary invasive ductal 
carcinoma of the breast and axillary node with metastasis demonstrated that 
fibronectin was upregulated in both varieties of isolated tumor compared to disease 
free mammary epithelium (52). Fibronectin is not only differentially expressed 
between normal and tumor breast tissue but also differentially upregulated when 
compared to other cancers such as lung squamous cell cancer, lung adenocarcinoma, 
and renal cell cancer (53). In fact, fibronectin is most prominently expressed in cell 
lines selected for enhanced lung colonization and is known as a “pro-metastatic” gene 
(51). FN1 is also upregulated in a highly lung metastatic breast cancer cell variant 
isolated from early lung metastasis (54). Bioactive Fn fragments released during 
remodeling of mammary tissue in post-lactational involution have also been associated 
with increased breast cancer invasiveness and metastasis to the lung, liver and kidney 
(55). This result correlates with the high occurrence of metastases in pregnancy-
associated breast cancer. These studies strongly indicate a role for fibronectin in breast 
cancer progression and metastasis. 
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FIBRONECTIN MATRIX ASSEMBLY 
 
Fibronectin mediates a wide range of cellular functions in normal cells which 
includes cellular interactions with the extracellular matrix (ECM), cell adhesion, 
migration, growth and differentiation (1). The single question of utmost importance 
regarding the function of fibronectin is the mechanism by which cells convert it from a 
relatively compact soluble protomer to an insoluble form of multimers visible by 
fluorescence microscopy. This is a highly regulated process that involves interaction 
between fibronectin and cell surface receptors, matrix components, as well as itself. 
The ability to interact with the variety of molecules to accomplish the formation of a 
complex meshwork is conferred in the unique structure and domains within 
fibronectin (1). 
 Fibronectin is secreted as a dimer composed of two subunits of 250-kDa 
fibronectin molecules linked covalently near the C-termini and after secretion, 
fibronectin is assembled into a fibrillar matrix through interactions with cell surface 
integrin receptors, other matrix components or via self association (Fig 1.3). The 
incorporation into the matrix occurs in a two step process. The first step is binding of 
fibronectin in a deoxycholate (DOC) soluble pool that is reversible. The second step 
forms a DOC insoluble pool and results in a multimeric insoluble matrix. (1,56). The 
assembly process is integrin-dependent and fibronectin-integrin interactions trigger 
sequential events involving extracellular comformational activation of fibronectin and 
intracellular organization of the actin cytoskeleton. During assembly, the 
conformational changes of fibronectin expose fibronectin-binding sites and promote 
intermolecular interactions that result in fibril formation (57). 
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Mao, Y. et al. (2005) Matrix Biol 24(6), 389-399 
Figure 1.3: Major steps of Fn fibril assembly: (A) Soluble Fn binds to α5β1 integrin 
via its cell binding domain. (B) Fn binding to integrins and other receptors (pink bars) 
induces reorganization of the actin cytoskeleton (green lines) and activates 
intracellular signaling complexes (silver circles). (C) Fn–Fn interactions results in 
fibrils formation. (57) 
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 (1) INTERACTIONS OF FN AND INTEGRINS 
Fibronectin is recognized by at least 10 different integrins. The first of such 
isolated is the α5β1 integrin, often referred to as the classical fibronectin receptor. It 
appears to be the main integrin attaching cells to fibronectin and has a partial role in 
controlling the assembly of fibronectin matrix around cells. (1,58,59). The region 
spanning the center of the Fn polypeptide chain in the ninth and tenth type III repeats 
binds to the α5β1 integrin (60). Extensive research had narrowed down the essential 
sequence for cell adhesion to several minimal integrin-recognition sequences. Two 
critical amino acid sequences in Fn are required for α5β1 integrin binding: an Arg-
Gly-Asp (RGD) sequence and a Pro-His-Ser-Arg-Asn (PHSRN) sequence (Fig 1.2). 
The well known RGD sequence is located in the tenth type III repeat.  The binding to 
this simple tripeptide sequence depends on many factors including the flanking 
residues, the three dimensional presentation of the sequence and individual 
characteristics of the integrin-binding pockets (1). The synergy site PHSRN in the Fn 
repeat III9 mediates binding of Fn to α5β1 integrin via interactions with α5. Binding of 
Fn to α5β1 integrin can also be achieved through interactions with N-terminal 
fragment that contains I1-9 and II1-2 and trigger distinct intracellular signals from those 
elicited through ligation with RGD (1). This PHSRN site has been implicated in 
regulating matrix metalloproteinase (MMP)-1-dependent invasion of human breast 
cancer and mammary epithelial cells (61). Other integrins that have been shown to 
bind fibronectin are α3β1, α4β1, αvβ1, αIIbβ3, αvβ3 αvβ6, α4β7 and α?β8 (62). Many 
of the other fibronectin binding integrins bind to the RGD sequence, but the α4β1 
integrin binds to fibronectin at a different site. The α4β1 binding site in fibronectin 
resides in the CS1 or V25 site that is located in the alternatively spliced V region of Fn 
(63-66). Studies have implicated functional differences between α4β1 and α5β1 in 
fibronectin matrix assembly (67, 68). 
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(2) INTERACTIONS OF FN AND OTHER MATRIX COMPONENTS 
 Fibronectin mediates a wide variety of cellular functions through the binding 
of molecules other than integrins. These include heparin, collagen/gelatin, and fibrin. 
The interacting domains of Fn to these molecules have been identified by proteolytic 
fragmentation or recombinant DNA analyses (8,69,70). Fn contains two major 
heparin-binding domains with the strongest binding site at the C-terminus (Heparin II) 
and a weaker binding site at the N-terminus (Heparin I). The Heparin II site also binds 
to glycosaminoglycan, chondroitin sulfate while Heparin I mediates Fn interactions 
with bacteria. The heparin binding domains of Fn is involved in cell adhesion in some 
cell types (1, 71). The collagen binding domain includes I6-9 and II1-2 and binds 
denatured collagen (gelatin) more effectively than native collagen. This domain has 
been implicated more in the clearance of collagenous materials than as a mediator of 
cell adhesion (1). The fibrin binding sites of Fn are Fibrin I and Fibrin II. Interactions 
at these sites have a role in cell adhesion and cell migration (1). 
 
(3) FN SELF ASSOCIATION 
Matrix assembly requires self association of fibronectin and involves domains 
within fibronectin that are highly specialized for Fn-Fn interactions (3,8,69,72). Two 
regions of fibronectin has been implicated in Fn binding (self association) and matrix 
assembly (3). The 70-kDa amino-terminal region was shown to be essential for matrix 
assembly while the type I repeats I1-5 within this region confer fibronectin binding 
activity. The 70-kDa amino-terminal fragment was shown to have saturable binding to 
fibroblast monolayers and to be required for de novo assembly of newly synthesized 
recombinant fibronectins into the extracellular matrix. A fragment containing type I 
repeats I1-5 can be covalently cross linked to fibronectin at the cell surface while 
deletion of the five repeats drastically reduced the binding ability of the fragment to 
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fibroblasts. An excess of the 70-kDa fragment and antibodies against repeats I1-5 had 
the ability to inhibit matrix assembly. A second site involved in fibronectin binding 
exists in a fragment spanning the first two type II repeats (II1-2) adjacent to the gelatin 
binding domain. The 56-kDa fragment spanning this region and antibodies raised 
against repeats within it also had the ability to inhibit fibronectin binding and matrix 
formation (3). Other regions involved in matrix assembly include the cell binding 
domain (3,67,73) and the carboxyl-terminal cysteines that form the interchain 
disulfide bonds in the Fn dimer (74).  
 
(4) INTERACTION OF FIBRONECTIN WITH DIPEPTIDYLPEPTIDASE IV 
(DPPIV) 
DPPIV (CD26) is a membrane bound ectopeptidase that modulates the 
activities of several cytokines, chemokines and hormones via its unique proteolytic 
activity preferentially cleaving N-terminal X-Pro or X-Ala dipeptides (75-77). 
CD26/DPPIV also exerts biological functions unrelated to its dipeptidase activity. Not 
only can DPPIV form heterodimers with FAP-alpha, associate with plasminogen 2, 
ADA, CD45, and CXCR4, it can also bind to the ECM proteins fibronectin and 
collagen (77).   
Binding of fibronectin to hepatocytes in suspension was first observed by 
Johansson utilizing an 85kDa cell binding peptide that lacks the gelatin- and heparin-
binding domains. The 85kDa peptide inhibited initial attachment of hepatocytes to 
immobilized fibronectin and bound to the cells in suspension at 4 degrees C in a time-
dependent, saturable, and partially reversible reaction (62). Piazza et al. later reported 
that initial binding of fibronectin to the cell surface where it was subsequently cross-
linked is accelerated by inhibitors of DPPIV (78). Kinetic studies revealed that 
increasing amounts of iodinated Fn were irreversibly incorporated into large covalent, 
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nonreducible complexes that fail to enter the stacking gel during SDS-PAGE. 
Nitrocellulose binding assays using 125I-labelled DPP IV purified from rat 
hepatocytes demonstrated a direct interaction of DPP IV with fibronectin. Fibronectin 
was found to bind DPP IV at a site distinct from its exopeptidase substrate recognition 
site (78). 
Studies were performed in this lab to identify the endothelial cell adhesion 
molecule responsible for binding multimeric fibronectin presented on the surface of 
metastatic breast cancer cells (polyFn), which mediates lung colonization, showed the 
responsible molecule to be the DPPIV expressed on rat lung capillary endothelia (79). 
Such adhesion could be inhibited in vivo and in vitro by soluble DPPIV and by 
antibody to Fn but not by soluble Fn (79). Immobilized DPPIV pulls down Fn 
multimers but not protomers from 35[S]-Met-labeled MTF7 cell extracts. MTF7 cells 
in suspension accumulate 125[I]-labeled Fn on their surface in a manner similar to that 
described above and in adherent cells, resulting in deoxycholate-insoluble and 
nonreducible multimers, seemingly forming a transglutaminase cross-linked matrix. 
These multimers assembled on tumor cell surface can be visualized as distinct 
globules under a fluorescent microscope (79). Soluble DPPIV binds to Fn-coated 
plastic (immobilized Fn) but such binding is not inhibited by soluble Fn, justifying the 
physiological relevant condition where the cancer cells are able to bind to endothelial 
DPPIV through its surface associated polyFn in a fibronectin rich environment in the 
plasma (79).  
A detailed study in our lab using proteolytic fragments and maltose-binding 
protein fusion proteins found that the DPPIV-Fn interaction to be mediated by the 
consensus motif T (I/L)TGLX (P/R)G (T/V)X on fibronectin. These DPPIV-binding 
sites are located in type III repeats 13, 14, and 15 (Fn III13, -14, and -15, respectively) 
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of fibronectin. Peptides spanning the DPPIV-binding domain of FNIII14 blocked 
DPPIV/polyFn adhesion and suppressed pulmonary metastasis (80). 
 
FN IN EPITHELIAL TO MESENCHYMAL TRANSITION AND INVASION 
 
 Tumor cells that migrate must first undergo a process known as epithelial to 
mesenchymal transition (EMT) to alter their phenotype into a less adhesive, more 
motile and spindle shaped cell that resembles cells from mesenchymal origin (81,82). 
EMT is a normal physiologic process that occurs during embryonic development, 
organogenesis, tissue growth and wound-healing and repair (83) but is also involved 
in the pathogenesis of many diseases and tumorigenesis. In breast cancer, EMT has 
been found to occur in 18% of tumors in vivo (84). EMT is defined as a variable 
proportion of tumor cells that express mesenchymal markers like vimentin and 
tenascin (84). EMT is involved in the appearance of different breast carcinoma types 
(85). Partial or complete loss of E-cadherin during carcinoma progression, which leads 
to poor prognosis, has been reported (85). Snail, a gene regulating EMT in Drosophila 
gastrulation, is expressed in areas of heterogenous tumors that are devoid of E-
cadherin and is also found in all ductal invasive carcinomas with lymph node 
involvement (86). On the other hand, twist, another embryonic regulator, is highly 
expressed in invasive lobular carcinoma (87). Suppression of twist also inhibits the 
lung metastatic ability of highly metastatic mammary carcinoma (87). Areas of tumor 
lesions harboring poorly differentiated tumor cells that exhibited mesenchymal 
features in mammary sections of Cripto-1 transgenic mice were stained positive for Fn 
as well as integrins αv,α3, β1 and β3, known Fn receptors (88), strongly correlating 
EMT to Fn. A blocking antibody of α5β1 integrin signaling resulted in a more 
epithelial morphology in EGF-treated cells while other integrin antibodies tested have 
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no effects (89). Inhibition of α5β1 integrin signaling also blocked EGF-mediated 
increase of EMT markers vimentin and snail and decrease of E-cadherin while 
application of Fn increased EGF-induced effects on EMT markers. These results 
indicate that α5β1 integrin signaling and Fn can modulate EGF-induced EMT in 
cervical cancer cells (89). α5β1 integrin has also been implicated in TGF 1-induced 
EMT in mammary epithelial cells (90). Direct evidence of EMT involvement in breast 
cancer has also recently been shown in three different oncogene-driven mouse 
mammary tumor models (91). These models found stromal fibroblasts associated with 
myc-induced tumors were of epithelial origin and these cells lacked cytokeratin and E-
cadherin expression while expressing mesenchymal specific markers vimentin and FN 
(91). However, EMT is not required for breast cancer invasiveness and metastasis 
because mice and human tumors lacking EMT also had metastatic potential (91). EMT 
presents one mechanism by which cancer progress to a more aggressive phenotype. 
Invasion of cells into a tissue can be a part of tumor progression or a part of 
normal cell processes. In cancer, invasion of cancerous cells into normal cells leads to 
metastasis. In inflammatory response or wound healing, migration of cells to the site 
of infection or wound site is a normal response (92).  Fn in the matrix can promote or 
prevent invasion. In the case where invasive tissue is migrating into an acellular 
extracellular matrix, such as during embryogenesis or wound repair, Fn promotes 
invasion. Migration fails when fibronectin is ablated, when cell-Fn interaction is 
blocked by antifunctional antibodies to Fn or integrin, and when RGD-containing 
peptide is used, and this typically leads to reduced invasion (92). In developing fetus, 
when Fn accumulation at the intimal cushion (smooth muscle in the center of arteries 
that keep arteries open) extracellular matrix is reduced, vascular smooth muscle 
invasion is blocked and the ductus fails to close properly after birth (93). If invasion 
occurs towards densely cellular tissue, Fn prevents invasion. Fn contributes to the 
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stabilization of the organization of tissues, such as in a developing amniote heart, 
where Fn stabilizes the contact boundary between the myocardium and the epicardial 
mesenchyme. Loss of crucial mediators of adhesion may result in pathological 
disorganization of tissues that leads to aggressive malignant invasion (92). An anti-β1 
blocking antibody inhibited invasion of both HT-1080 fibrosarcoma cells and MDA-
MB-231 breast carcinoma cells through Matrigel basement membrane (94,95). Anti-
α5 blocking antibody also inhibited MDA-MB-231 invasion in the presence of 
chemoattractant but not in the absence of it (95). In this case, the α5 integrin may be 
functioning as a chemoattractant and not adhesion receptor to promote migration of 
cells towards Fn (95). Similarly, in cervical cancer, EGF stimulated cancer cell 
invasiveness was abolished by α5β1 integrin blocking antibody (89). Comparison of 
normal and fibrotic lung fibroblasts revealed that Fn signaling through α5β1 integrin 
mediates migration/invasion while Fn signaling through α4β1 integrin suppresses 
migration/invasion (96). The α4 integrin has also been found to be inversely correlated 
to invasive potential in B16 melanoma cells (97). The functional roles of Fn in EMT, 
cell migration and invasion tightly correlate with its role in tumor progression. 
 
FIBRONECTIN IN METASTASIS  
 
 The role of Fn in metastasis cannot be simply stated. In some cases, Fn 
contributes to metastasis and is upregulated in metastatic variants of cancer cells (98-
105). In other cases, Fn is found to be negatively correlated to metastasis (51,95,106-
110). Various studies on the same type of cancer have pointed towards different 
functional consequences of Fn expression.  
 There are generally two broad classes of in vivo metastasis models. The 
“experimental” metastasis models involve injection of tumor cell suspensions into 
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mice and quantitation of the number or sizes of the metastatic colonies at the 
metastatic organ. This model studies the later steps of metastasis, skipping the early 
steps of detachment from the primary tumor mass and invasion into the vessels. The 
“spontaneous” metastasis models are more complicated and involve the implantation 
of tumors or cells into mice. This model measures the earlier steps including 
detachment, intravasation leading to the final steps of adhesion, tumor arrest and 
migration into the secondary metastatic organ (95).  
Fn can have a negative role in metastasis. Fn has been shown to suppress 
transformed phenotypes in some studies. Overexpression of pFn in human 
fibrosarcoma cells leads to suppression of tumor features such as a flattened 
morphology, reduced cell migration and reduced tumor growth (98). Similarly, inverse 
correlation has also been shown between Fn expression and metastatic potential. 
Comparison between non-metastatic prostate cancer cell subtype and metastatic 
subtype (99) and between moderate-metastatic and high-metastatic murine mammary 
adenocarcinoma subtypes (100) showed decreased Fn expression in non-metastatic or 
lower metastatic subtypes. Independent experiments that perturb Fn-integrin 
interactions also showed negatively correlation of Fn and metastasis. Injection of mice 
with RGD-containing peptides reduced experimental metastasis of murine melanoma 
cells (101).  Intraperitoneal administration of super-Fn (induced multimeric form of 
fibronectin with enhanced adhesive properties) into mice reduced lung colonization in 
both experimental and spontaneous metastasis models of KRIB osteosarcoma, C8161 
melanoma or HT-29 carcinoma cells (102). Studies using the MM3 murine mammary 
adenocarcinoma cell line showed inverse correlation between Fn expression and 
metastatic potential. The highly metastatic MM3 does not express Fn protein or 
mRNA while the parental M3 moderately expresses Fn and forms Fn ECM (103). 
Global gene expression comparison between the two cell lines revealed only two 
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genes significantly down regulated in MM3 , one of which is Fn, reduced by 19 fold 
(104). LMM3 tumor cells, derived from MM3 spontaneous lung metastasis, like its 
parent cell line also does not express Fn. Expression of wild type Fn and Fn lacking 
RGD, which does not form ECM fibrils, in LMM3 cells is shown to be sufficient to 
reduce the metastatic potential of cancer cells (105). These studies provide a model in 
which Fn has a negative impact on cancer metastasis. 
 However, many studies also strongly suggest a role of Fn in metastasis. Global 
gene profile revealed 3-fold expression of Fn in breast tumors (51), up to 28 fold in 
colorectal tumors (106), 2.83 fold in head and neck squamous cell carcinoma (107). 
Fn expression was positively correlated with lymph node involvement and mortality 
risk of breast cancer (108). In an experimental metastasis model studying B16-F10 
murine melanoma cells, the synthetic peptide GRGDS, derived from Fn IIICS cell-
binding domain, specifically inhibited the number of lung colonies and results show 
that the peptide may be interfering with multiple fibronectin-mediated events at 
different steps of the metastatic process (109). A peptide consisting of Fn central cell-
binding domain and heparin-binding domain (CBD-HepII) was able to suppress lung 
metastasis of B16 melanoma (110) and hepatic metastasis of hepatocarcinoma (111). 
The importance of Fn-Tumor cell interactions in metastasis can be further supported 
by the studies that showed the abilities of anti-α5 and anti-β1 monoclonal antibodies to 
inhibit experimental metastasis in MDA-MB-231 cells. In spontaneous metastasis 
models, treatment of mice bearing mammary carcinoma transplants with anti-β1 
polyclonal antibodies reduced the size of the metastatic colonies but not the number, 
possibly indicating inhibition of tumor cell interations with the surrounding 
extracellular matrix (95).  
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SITE SPECIFIC METASTASIS 
 
In the process of hematogenous metastasis, cancer cells break away from the 
primary tumor, enter the blood stream, arrest at the vasculature of a secondary organ 
and either form colonies at the endothelium adhesion site (112) or extravasate to form 
tumor colonies completing the metastatic cascade (113) (Fig 1.4). Studies have 
followed labeled tumor cells through the course of hematogenous spread and found 
that cells initially arrest in the microvasculature of the first organ they encounter. At 
this site, most tumor cells die (114) and a few survive either to form colonies at that 
site or colonize another tumor specific metastatic organ (115). Metastasis was once 
believed to be a mechanistic phenomenon but evidence supports involvement of organ 
specific molecules in the specific recognition of tumor cells to secondary organs of 
colonization. This is known as the “seed-and-soil hypothesis (190).The fact that 
tumors have select specificity for certain organs during metastasis is supported by 
clinical assessment (116). For instance, prostatic carcinomas and small cell 
carcinomas of the lungs preferentially colonize bones and the brain, respectively, on 
the other hand, breast carcinomas most frequently metastasize to the lungs, but also to 
liver, bones, brain, and adrenals (79). Tracking of GFP tagged tumor cells found that 
the cells were mainly in pre-capillary arterioles, which had diameters larger than 
tumor cells, indicating that cells were not merely arrested by capillary trapping. The 
same study also found extravasation to be a rare event, with no intact cells surviving 
extravascularly for more than 48 hours, although occasional presence of invadopodia 
were noted intravascularly (112). Although the extravascular metastasis model is 
based on the fact that loss of cell contact leads to accelerated cell death in blood 
circulation, anchorage independent growth in suspension in tumor cells and 
facilitation of cell proliferation by endothelial attachment have been shown, which  
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Figure 1.4: The main steps in the formation of a metastasis. (190) 
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further supports the intravascular metastasis model (112). Opposing to the 
extravascular metastasis model, which tumor cells extravasate at the endothelial 
attachment site to form metastatic foci extravascularly, the intravascular metastasis 
model supports that metastatic colonies originate from intravascular cells, form 
micrometastases within the vasculature, and finally the colonies will outgrow the 
vessels and disrupt the vascular walls (112). 
Vascular arrest of cancer cells mediated by “organotypic” molecules is 
responsible for the initial selection of an organ for metastasis (117-119). For example, 
the lung endothelial cell adhesion molecule-1 (Lu-ECAM-1; bCLCA2, bovine calcium 
activated chloride channel 2) characterized in this laboratory selectively binds lung-
metastatic melanoma cells and its expression on the endothelia of pulmonary venules 
correlates with the formation of melanoma metastases at these sites (120). Monoclonal 
antibodies against Lu-ECAM-1 inhibit colonization of the lungs by lung-metastatic 
murine B16 melanoma cells but have no effect on lung colonization by other types of 
lung-metastatic cancer cells indicating a tumor cell specific adhesion molecule that 
mediates lung colonization (79,120). Colonization of the lungs by human breast 
cancer cells has been shown to be mediated by breast cancer β4 integrin and 
endothelial hCLCA2, the human counterpart of bCLCA2 (121). The CLCA family 
members comprise of one group of endothelial tumor homing receptors that facilitate 
vascular arrest of tumor cells.  
Utilizing outside out luminal membrane vesicles, we also show that more 
vesicles isolated from rat lung microvascular endothelia binds to lung metastatic rat 
breast carcinoma cells compared to nonmetastatic counterparts (79,122,123). Vesicles 
isolated from nonmetastatized organ (e.g., hind leg muscle) showed no binding 
preference for lung-metastatic or nonmetastatic mammary carcinoma cells. 
Monoclonal antibodies against the lung-derived endothelial vesicles inhibit specific 
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adhesion of the vesicles to lung-metastatic breast cancer cells. The antibody 
recognizes a 110-kDa membrane glycoprotein which was found to be dipeptidyl 
peptidase IV (DPP IV; also known as CD26 or gp110) (123). Studies have previously 
identified association between cell surface expression of Fn and lung metastasis of 
rhabdomyosarcoma cells and the DPP IV ligand was identified as tumor cell surface-
associated Fn (124). Fibronectin assembles on breast cancer cell surfaces into 
multiple, randomly dispersed globules from cellular and plasma Fn. The level of Fn 
surface expression correlates to the tumor cells' ability to bind to DPP IV and 
metastasize to the lungs. Soluble DPPIV blocks DPPIV/Fn mediated adhesion and 
metastasis while anti-DPPIV and anti-Fn mAb blocks adhesion. Adhesion is 
unaffected by soluble plasma FN (pFn) and indicates the ability of cancer cells to 
arrest through this mechanism under high plasma Fn conditions in the blood stream. 
The ability of many cancer cells to capture Fn molecules on their surface and to 
augment such deposits by Fn self-association during passage in the blood suggests that 
DPP IV/Fn binding may be a relatively common mechanism for lung metastasis (79). 
The CLCA/β4 interaction and the DPPIV/Fn interaction demonstrate the importance 
of vascular addresses in the adhesion step in metastasis. 
 
POLYMERIC FIBRONECTIN ON SUSPENDED BREAST CANCER CELLS 
MEDIATES LUNG METASTASIS 
 
The molecular foundation of the original immobilization of Fn on the surface 
of breast cancer cells is poorly understood. It seems that rat breast cancer cells 
growing as a solid tumor mass in syngeneic animals support the synthesis of a Fn-
containing matrix (116). After tumor cells escape the primary tumor, they become 
blood-borne and travel passively with the blood stream to other organ sites (113,119). 
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In the pFn-rich environment of the plasma, tumor cells decorated with a light coat of 
cellular Fn use this Fn scaffold to attain pFn molecules for the buildup of a prominent 
Fn coat that is visualized as multiple, densely distributed Fn globules by 
immunocytochemistry. This suggests that the initial Fn binding to the cell surface 
occurs around focal adhesion points from which polymerization is then initiated by Fn 
self-association (125-128). Such adhesion points are anticipated to be sites of integrin 
clusterings, most likely the classic Fn receptor α5β1 (67,129,130). An alternative 
mechanism may be that a cellular Fn-α5β1 complex forms intracytoplasmically (e.g. 
in Golgi vesicles) and serves as a scaffold for build up upon transport to and 
incorporation into the plasma membrane (79). 
 The Fn buildup on cancer cell surfaces is comparable with that reported first 
for normal confluent, adherent cell layers of fibroblasts (56). A 4 hour incubation of 
lung-metastatic breast cancer cells with 125I-pFn results in cell surface-associated Fn 
that can be harvested as DOC-soluble and DOC-insoluble fractions. The multimeric 
Fn on breast cancer cells and normal hepatocytes, both grown in suspension, 
progressively converted to nonreducible, seemingly covalently bonded Fn complexes 
(131) not observed on anchorage-dependent normal fibroblasts (56). This conversion 
is possibly mediated by a cancer cell-associated transglutaminase activity, similar to 
hepatocytes (131). The similarities between the Fn assembly in suspended, blood-
borne breast cancer cells and adherent fibroblasts suggest that commons receptors and 
signaling molecules might be shared between the two pathways. 
 
SIGNALING EVENTS IN FIBRONECTIN ASSEMBLY  
 
 Fibronectin matrix assembly involves regulated intracellular signaling events 
that include binding to integrins, organization of the actin cytoskeleton and stimulation  
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of cell contractility and activation of kinase cascades (132) (Fig 1.5). A number of 
studies have established that binding of Fn by specific integrins is critical in initiating 
Fn matrix assembly. Fn fragments that contain the RGD integrin binding site or 
antibodies recognizing the integrin binding site inhibited Fn matrix assembly in 
cultured cells and developing amphibian embryos (133-138). Also, antibodies to α5β1 
integrin decreased the deposition of Fn into extracellular matrix by fibroblasts 
(72,133,139,140). The role of Fn-binding integrins in Fn matrix assembly has been 
extensively studied in Chinese hamster ovary (CHO) cells. Overexpression of α5β1 in 
CHO cells increased Fn deposition in extracellular matrix (141) while CHO B2 cells 
deficient in α5 did not assemble plasma Fn into the extracellular matrix (67). 
Transfecting the CHO B2 cells with a full-length α5 chain completely restored fibrillar 
Fn matrix assembly (67). These studies determined an important role of α5β1 integrin 
in supporting Fn matrix assembly by CHO cells. On the other hand, cells are also able 
to support Fn matrix assembly through other integrins. One example of such is 
fibroblastic cells derived from α5 integrin null mutant embryos being able to assemble 
a Fn matrix in the absence of α5β1 (142). The primary role of α5β1 integrin in Fn 
matrix assembly seems to involve the initiation step of Fn matrix assembly, since Fn 
mutants lacking the α5β1 integrin binding site could not be assembled into Fn matrix 
if not in the presence of native Fn (74,143). 
Integrin links extracellular matrix (ECM) to cytoplasmic molecules mediating 
initiation of intracellular pathways that control cellular function. One cytoplasmic 
signaling molecule that is phosphorylated in response to integrin binding to ECM is 
FAK. FAK controls cell adhesion and spreading, migration, cell survival and 
proliferation. FAK directly interacts with downstream molecules such as Src, 
phosphatidylinositol 3-kinase (PI3-kinase) and Grb7 and these molecules have been 
implicated in regulation of early Fn fibrillogenesis (5,144-146). Cells lacking Src  
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Figure 1.5: Model of Fn matrix assembly. (57) 
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family kinases, cells treated with Src and PI3-kinase inhibitors, and FAK-null cells 
and cells with increased Src expression and activity are all associated with a decrease 
in fibronectin assembly (8,147). These proteins are regulated by phosphorylation on 
specific tyrosine residues and phosphorylation events may vary depending on the cell 
type (5). 
Integrin ligation can also trigger activation of certain MAP kinases, including 
extracellular signal-regulated kinase (ERK) 1 members and JNK (JUN kinase) (148-
151). Different types of MAP kinases have distinct pathways and functions. ERK 
activation have been linked to EGF growth factor response pathways, while JNK is 
not activated by EGF in most cells but is activated by inflammatory cytokines or stress 
response such as UV irradiation (151,152-154). One study using inhibitors found that 
herbimycin A and genistein blocked the activation of both types of MAP kinases 
induced by cell binding to FN coated beads, while Cytochalasin D inhibited the ERK 
pathway and have no effect on SAPK/JNK1 pathway. The study showed that integrins 
can mediate activation of two distinct serine/threonine kinase pathways with different 
kinetics and different responses to disruption of the actin cytoskeleton (154).  
A subset of cytoskeletal proteins including tensin, α-actinin, talin and vinculin 
does not seem to require tyrosine phosphorylation to accumulate locally after integrin 
ligation (154,155). In contrast, another set of cytoskeletal proteins including paxillin 
and F-actin, and a group of signaling proteins such as Ras, phospholipase Cγ and ERK 
require tyrosine phosphorylation for accumulation (155). Cytoskeletal responses to 
integrin ligation can be studied using beads coated with molecules that interact with 
integrins. Fibronectin-coated beads induced the local accumulation of a variety of 
cytoskeletal molecules, including vinculin, talin, α-actinin, and F-actin (154,156-159). 
This further underlies the importance of cytoskeletal participation in the process of 
fibronectin matrix assembly. 
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Oncogenes can also affect fibronectin assembly through regulation of integrin 
function and localization. Ras proteins, which are small GTPases, link cell surface 
receptors to intracellular effector pathways regulating cell proliferation, differentiation, 
and survival (155). Ras proteins exert cell functions through the activation of several 
downstream effectors, including Raf, Rac, phosphatidylinositol 3-kinase (PI3K), and 
Ral (160). Through Raf, Ras activates MAPK/ERK kinase (MEK), which then 
phosphorylates ERKs (161-163). Activation of Raf-1 impedes the ability of α5ß1 
integrin to mediate Fn matrix assembly (165). The suppression is similar to what 
occurs in v-src-transformed cells and correlates with activation of ERK. HT1080 
human fibrosarcoma cells possess one activated N-ras allele and can be stimulated to 
assemble Fn matrix by activation of integrins using Mn2+ or ß1 integrin-activating 
antibody or by inhibition of Ras signaling through ERK (165). In summary, mutation 
of at least two oncogenes, ras and src, have negative effects on Fn matrix assembly 
and, in some cells, exert their effects through a common downstream effector, ERK.  
 Integrin ligand binding affinity can also be regulated via inside-out signaling, 
in which intracellular components are able to control extracellular matrix assembly by 
modulation of ligand preference through interaction with the cytoplasmic tail of 
integrins. (133,166-170). Constitutively active R-Ras expressed in CHO cells with 
αIIb3 integrin activated the integrin and caused an increase in Fn matrix assembly 
(171), whereas activation of Raf-1, probably via the MAPK pathway, suppresses 
integrin activation and Fn matrix assembly (164). One report shows that 
overexpression of ILK in epithelial cells dramatically stimulated integrin-mediated Fn 
matrix assembly (133). ILK, a serine/threonine kinase, binds to the cytoplasmic 
domains of both β1 and β3 integrins and phosphorylates the β1 cytoplasmic domain in 
vitro (172). These studies show that cells control integrin activity and Fn matrix 
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assembly via interactions of cytoplasmic regulatory proteins with integrin cytoplasmic 
domains (133).  
 However, integrins do not act alone in transmembrane signaling in Fn matrix 
assembly (132). Cells with impaired proteoglycan synthesis showed defective Fn 
matrix assembly, and this has been attributed to reduced activity of syndecans, 
transmembrane proteoglycans that can bind Fn (173, 174). The major syndecan in 
fibroblasts, syndecan-2, has been shown to have an indirect regulatory effect on matrix 
assembly through truncation studies. A truncated version of syndecan-2 lacking a part 
of its cytoplasmic tail blocks Fn assembly in a dominant negative way. On the other 
hand, syndecan-2 without its entire cytoplasmic tail had no effect on matrix formation 
(175). Another syndecan, syndecan-4, has a more direct effect on Fn assembly. 
Syndecan-4 cooperates with integrins in regulation of Rho-dependent cell adhesion, 
spreading and actin organization (176). Concomitant ligation of α5β1 integrin and 
syndecan-4 increases active Rho(177) and phosphorylated FAK and Rho and FAK, 
when both stimulated, have been shown to favor Fn matrix assembly (178). 
Another important signaling molecule that has been implicated in fibronectin 
assembly is PKC. (179-182). PKC activation has been shown to increase Fn synthesis 
and fibrillogenesis in a number of cell types, cinluding pulmonary fibroblasts, retinal 
pigment epithelial cells, vascular smooth muscle cells, osteoblasts, hyperglycemic 
mesangial cells and Xenopus cells (132, 182, 183-187). Activation of PKC increases 
I125-labeled Fn binding to the cell surface while inhibition of PKC resulted in a rapid 
decrease in Fn binding (179). The PKC activator TPA increases extracellular assembly 
of Fn fibril while the PKC inhibitor forskolin decreased assembly. Moreover, TPA 
increased α5 integrin clustering and surface expression while PKC inhibitors inhibited 
clustering; implicating that PKC regulates the dynamic assembly of Fn through 
modulation of integrin distribution (180,181). PKC also binds to the cytoplasmic tail 
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of clustered syndecan-4 (188-189) and may act on Fn assembly through syndecan-4. 
The strong connection of PKC with integrins and syndecan could potentially be the 
pathway regulating cell surface polyFn assembly in blood-borne cancer cells. 
 
SUMMARY AND GOALS OF THIS STUDY 
 
 In summary, gene expression profiling of breast cancer of different stages and 
metastatic preference shows that fibronectin is upregulated in breast cancer. 
Fibronectin interacts with integrins, matrix components and itself during matrix 
assembly through its integrin interaction sites, collagen, heparin or fibrin binding sites, 
and self association sites, respectively. Cellular fibronectin has distinct domains from 
plasma fibronectin and may play a different role in fibronectin assembly. Cells are 
also able to interact with fibronectin and transduce inside-out or outside-in signals 
through different integrin receptors. Fibronectin also interacts with DPPIV. In breast 
cancer cells, multimeric fibronectin (polyFn) assembled on the surface of the cells 
interact with DPPIV on lung endothelial cells facilitating lung vascular arrest and 
promotes lung metastasis. The level of polyFn surface expression correlates with 
cancer cells’ ability to metastasize to lungs.  The intracellular mediator of the process 
of polyFn assembly has not been identified, and a further investigation into the 
regulatory mechanism of fibronectin assembly on the surface of these breast cancer 
cells might bring forward new insights and novel strategies into the potential targets 
available for anti-metastatic therapy in breast cancer patients. The goal of this study is 
to examine the related pathways previously known to be associated in signaling 
pathways of adherent cell fibronectin matrix assembly in order to discover the 
molecule(s) regulating polyFn assembly and breast cancer cell lung metastasis. 
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THE SURFACE OF BLOOD-BORNE RAT BREAST CANCER CELLS TO 
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ABSTRACT 
 
 Malignant breast cancer cells that have entered the blood circulation from 
primary mammary fat pad tumors or are grown in end-over-end suspension culture 
assemble a characteristic, multi-globular polymeric fibronectin (polyFn) coat on their 
surfaces. Surface polyFn is critical for pulmonary metastasis, presumably by 
facilitating lung vascular arrest via endothelial dipepidylpeptidase IV (DPP IV; 
CD26). Here, we show that cell-surface polyFn assembly is initiated by the state of 
suspension, is dependent upon the synthesis and secretion of cellular Fn, and is 
augmented in a dose- and time-dependent manner by plasma Fn (pFn). PolyFn 
assembly is regulated by PKCε, which translocates rapidly and in increasing amounts 
from the cytosol to the plasma membrane and is phosphorylated. PolyFn assembly is 
impeded by select inhibitors of this kinase, i.e., bisindolylmaleimide I, Ro-32-0432, 
Gö6983, and Rottlerin, by the PMA-mediated and time-dependent loss of PKCε 
protein and decreased plasma membrane-translocation and, more specifically, by 
stable transfection of lung-metastatic MTF7L breast cancer cells with siRNA-PKCε 
and dominant-negative PKCε constructs (e.g., RD-PKCε). Inability to assemble a cell 
surface-associated polyFn coat by knockdown of endogenous Fn or PKCε impedes 
cancer cells from metastasis to the lungs. The present studies identify a novel 
regulatory mechanism for polyFn assembly on blood-borne breast cancer cells and 
depict its effect on pulmonary metastasis. 
 
INTRODUCTION 
 
 Fibronectin (Fn) is a “pro-metastatic” gene that is overexpressed in several 
malignancies (1-7) and, most prominently, in cancer cell lines selected for enhanced 
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lung colonization (8-11). This pro-metastatic role of Fn is multifaceted, affecting 
several steps of the metastatic cascade by modulating cell adhesion, motility/invasion, 
cell cycle progression, and cell survival (reviewed in refs. 12-16). By analyzing cancer 
cells that had entered the blood circulation from malignant breast cancers implanted 
into the mammary fat pad of rats or mice, we discovered that blood-borne tumor cells 
were decorated with a unique, multi-globular coat of polymeric Fn (polyFn) (9,17). 
PolyFn aggregates appeared to arise from focal accumulations of endogenous, cell 
surface-immobilized (‘linearized’) Fn, which served as scaffolds for further Fn-self-
assembly from Fn recruited from blood plasma (pFn) (9). Aggregates typically 
became increasingly deoxycholate-insoluble as they increased in size with time of 
incubation of suspended cancer cells in serum-containing medium in vitro. 
Biochemically, aggregates impressed as prominent, insoluble (covalently bonded) Fn 
polymers sitting on top of the stacks of SDS-polyacrylamide gels and, 
immunocytochemically, as large globules randomly dispersed over the entire cancer 
cell surface (9). This “cluster arrangement” of polyFn was shown to have the 
following functional implications: First, the conversion of Fn from the globular state 
of soluble Fn to the “linearized” state of insoluble, surface-associated Fn aggregates is 
associated with exposure of a novel, cryptic binding domain for the lung endothelial 
cell addressin dipeptidylpeptidase IV (DPP IV) (9,17-21). This DPP IV-binding 
domain is present as consensus motif in each of the 13th, 14th, and 15th type III repeats 
of Fn (17). Second, the DPP IV binding specificity for linearized (polymeric), but not 
for globular (soluble) pFn allows tumor cell adhesion to endothelial DPP IV in the 
presence of high pFn concentrations (9). Third, the large Fn aggregates on cancer cell 
surfaces allow multiple binding interactions with endothelial DPP IV molecules, 
thereby generating adhesion strengths between cancer cells and endothelial cells that 
are able to withstand the rigors of hemodynamic shear stresses (9). The importance of 
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the Fn/DPP IV-docking mechanism is substantiated by our discovery that synthetic 
peptides directed against the DPP IV-binding domain in the 13th, 14th, or 15th type III 
repeats of Fn as well as a polypeptide encompassing the bulk of the extracellular 
domain of DPP IV dramatically impeded pulmonary metastasis in the MT rat breast 
cancer model (19,20). These data are consistent with our finding that colonization of 
the lungs was greatly diminished in Fischer 344/CRJ rats, in which DPP IV is mutated 
causing a significantly decreased DPP IV protein expression in pulmonary endothelia 
(21), as well as in DPP IV(-/-) mice (19).  DPP IV(-/-) mice injected with lung-
metastatic cancer cells lived significantly longer than their wild-type counterparts, an 
outcome granted by the formation of significantly fewer and smaller lung colonies 
(Cheng, unpublished data). 
 Although we have firmly established a critical dependence between the cancer 
cells’ ability to assemble an insoluble, globular polyFn-surface coat and lung 
colonization in an experimental metastasis model (9,17), we still do not know whether 
blood-borne cancer cells use their own cellular Fn (cFn) or rely on ubiquitous pFn to 
assemble their polyFn surface coat, how cancer cells regulate the polyFn build-up, and 
how Fn cell surface deposits are transformed into covalently bonded, insoluble 
aggregates (9). To answer some of these questions we examined polyFn genesis in 
lung-metastatic MTF7L rat breast cancer cells subjected to end-over-end (EoE) 
suspension culture in serum- or pFn-containing medium, which together induce and 
augment the build-up of a polyFn surface coat similar to that observed on tumor cells 
that have entered the blood circulation (9). The data presented here show that 
assembly of the “pro-metastatic”, multi-globular polyFn surface coat on MTF7L 
breast cancer cells depends upon the synthesis and secretion of endogenous, cellular 
Fn (Fn1: EDA+EDB+IIICS120-Fn) and is regulated by membrane-translocation and 
Ser/Thr-phosphorylation of protein kinase C epsilon (PKCε). Inhibitors of protein 
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synthesis, protein secretion, and novel PKC isoforms (nPKCs) as well as transfection 
of MTF7L cells with the PKCε regulatory domain (RD) or PKCε siRNA species all 
substantially decrease the cancer cells’ ability to assemble a polyFn surface coat. 
Functionally, inability to assemble polyFn is associated with failure to colonize the 
lungs. Together, our studies provide novel insights of the regulation of Fn in 
suspended (blood-borne) breast cancer cells and provide a renewed appreciation for 
the previously recognized role of Fn in metastasis (1-7). 
 
MATERIAL AND METHODS 
 
Antibodies and Reagents   
 Rabbit anti-PKCδ, -PKCε, PKCη, PKCθ, PKCζ and anti-hemagglutinin tag 
(HA-tag) polyclonal antibodies, and mouse anti-Fn (raised against a region in the 
human Fn-EDA domain; human- mouse- and rat-specific) monoclonal antibody (anti-
Fn[EDA]) were from Santa Cruz Biotechnology (Santa Cruz, CA), rabbit anti-Fn 
polyclonal antibodies that recognized pFn and cFn from both bovine and rat (anti-
Fn[pan]: does not crossreact with fibrinogen,  vitronectin, laminin, collagen type IV) 
from Sigma (St. Louis, MO), rabbit anti-PKCε polyclonal antibodies from Upstate 
(Lake Placid, NY), mouse anti-PKCε used for immunoprecipitation from BD 
Biosciences (San Jose, CA), phycoerythrin (PE)-conjugated donkey anti-rabbit, PE-
conjugated goat anti-mouse, horseradish-peroxidase (HRP)-conjugated  donkey anti-
rabbit, and HRP-conjugated goat anti-mouse antibodies from Jackson 
ImmunoResearch (West Grove, PA), and rabbit anti-PKCα, -vinculin, and -actin from 
Dr. Guan (Cornell University). Pertussis toxin (Gαi inhibitor), PD98059 (MEK1/2 
inhibitor), SU6656 and PP2 (Src family kinase inhibitors), Wortmannin and 
LY294002 (PI3K inhibitors), JAKI (Janus-family kinase 1/2 inhibitor), and Y27632 
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(ROCK1/2 inhibitor), U73122 (inhibitor of phosphatidyl-inositol-specific 
phospholipase C [PI-PLC]), and the PKC inhibitors calphostin C, Gö6976, HBDDE, 
bisindolylmaleimide I (BIM I), Gö6983, BIM XI (Ro-32-0432), Rottlerin, Brefeldin 
A, monensin, and cycloheximide were from EMD Chemicals (San Diego, CA). Fetal 
bovine serum (FBS) was purchased from Gemini Bio-Products (Woodland, CA). Fn-
free FBS (FFS) was generated by successive gelatin- and anti-Fn antibody affinity 
chromatography (22). All other chemicals and reagents were from Sigma. 
 
Cell Cultures   
 MTF7L cells were derived from a lung-metastasis generated by tail-vein 
injection of MTF7 breast cancer cells (obtained from Dr. D.R. Welch, University of 
Alabama at Birmingham, Birmingham, AL) into Fischer 344 rats. At an i.v. 
inoculation dose of 2x105 cell per rat, MTF7L cells consistently produce in excess of 
400 lung colonies. Cells were grown in culture in Dulbecco’s Modified Eagle Medium 
(DMEM) containing 10% heat-inactivated fetal bovine serum (FBS). For EoE 
suspension culture, MTF7L cells were grown to 80 to 90% confluence, then removed 
from the growth surface by trypsinization [0.25% trysin, 0.02% EDTA in phosphate-
buffered saline (PBS); 10 min, 37°C], washed twice in DMEM containing 10% FBS, 
and subjected to EoE suspension culture for 1 hour (or as indicated) in 2ml-centrifuge 
tubes in DMEM plus 20% FBS at a concentration of 5x106 cells/ml (9,17,20). Tumor 
cells were used for all experiments within 10 passages from frozen stocks that were 
tested for metastatic performance immediately prior to freezing. 
For metabolic labeling, MTF7L cells in logarithmic growth phase were labeled with 
[35S]-methionine (0.33 mCi/3-ml) in methionine-free DMEM (both from MP 
Biomedicals, Solon, OH) containing 20 µM methionine and 10% dialyzed, Fn-free 
FBS as previously described (9). For [32P]-labeling, cells were serum-starved 
53 
 
overnight, then incubated for 4h in phosphate-free DMEM containing 100 µCi/ml of 
[32P]orthophosphate (ICN Biochemicals, Irvine, CA), washed in three changes of PBS. 
Labeled cells were subjected to EoE suspension culture as describe above, and 
immediately processed for biochemical analyses. 
 
Plasmids Constructs, Transfection, and Selection 
 The constructs wtPKCε, RD-PKCε, and RD-PKCη cloned into pEGFP-N1 
were obtained from Dr. C. Larsson (Lund University, Malmö, Sweden) (23) and 
wtPKCδ and RD-PKDδ cloned into pcDNA3.1 from Dr. D. Mayer (Deutsches 
Krebsforschungszentrum, Heidelberg, Germany) (24). For siRNA knockdown of 
protein expression the following nucleotide (nt.) sequences were cloned into 
pRNAU6-hygro vector (GenScript, Piscataway, NJ): nt. sequence #1 [5’-
acatgagactggtggctat-3’ (NM_019143.1, nt. 681-699)] and nt. sequence #2 [5’-
aacaaatctcctgcctgggac-3’ (NM_019143.1, nt. 4452-4472)] (25) for rat Fn1; nt. 
sequence #3 [5’-atggtagtgttcaatggc-3’ (NM_017171.1, nt. 194-211)] (26);  nt. 
sequence #4 [5’-ccaactctattgctgcttc-3’ (NM_017171.1, nt. 1603-1621)] for rat PKCε; 
and nt. sequence #5 [5’-aactcgcacatagcgactctg-3’] for the non-specific control 
sequence. The siRNA plasmid pKD™-PKCδ-v6 was purchased from Upstate (Lake 
Placid, NY). All plasmid constructs were verified by double-stranded sequencing. 
 MTF7L cells grown to 70% confluence were transiently transfected with above 
vector constructs or vector alone using LipofectAMINE™ Plus as described by the 
manufacturer (Invitrogen, Carlsbad, CA). Transfection rates assessed by expression of 
GFP that is either tagged to the cDNA of interest or co-transfected at a ratio of 1:50 
with the cDNA of interest were 20-30%. Cells were used in the various assays 48h 
after transfection unless otherwise stated. Stable clones were obtained by hygromycin 
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selection (750µg/ml). In some cases, hygromycin-selected clones were further selected 
by fluorescence-activated cell sorting (FACS) for optimal expression. 
 
Flow Cytometry 
 FACS was used to quantify Fn expression on MTF7L breast cancer cell 
surfaces (9,17). Tumor cells that had been subjected to EoE suspension culture were 
washed twice in DMEM containing 1% bovine serum albumin (BSA), then incubated 
with rabbit anti-Fn[pan] antibody diluted 1:100 in PBS containing 1%BSA (PBS-
BSA) for 1h at 4°C . After washing in PBS-BSA, tumor cells were stained with 
phycoerythrin (PE)-conjugated donkey anti-rabbit antiserum in PBS-BSA for 1h at 
4°C and fixed in 2% paraformaldehyde in PBS. In select experiments, cells were 
stained with mouse anti-Fn[EDA] (diluted 1:50) and PE-conjugated goat anti-mouse 
antiserum. FACS analysis was performed on a Coulter Epics Profile (Coulter 
Electronics, Hialeah, FL). Nonspecific fluorescence was accounted for by incubating 
tumor cells with non-immune rabbit serum instead of primary antibody. To quantify 
the effect of overexpressed or knocked-down proteins on polyFn assembly, we 
generated bivariate distributions of red fluorescence (y-axis: cells stained with anti-Fn 
antibodies and PE-conjugated secondary antibodies) and green fluorescence (x-axis: 
same cells expressing GFP-tagged protein or co-transfected with GFP and cDNA of 
interest). The levels of polyFn expression in the cell population that emitted high GFP 
fluorescence were taken as a reflection of the effect of the transfected cDNA on 
polyFn assembly. To assess the effect of inhibitors of cell signaling, tumor cells were 
incubated with inhibitor 30-min prior to (adherent) and throughout EoE suspension 
culture, then subjected to polyFn quantification as described above. Controls were 
tumor cells incubated in equimolar inhibitor solvent concentration. 
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Semiquantitative RT-PCR Analyses 
 Total RNA was prepared from MTF7L grown as adherent monolayers or in 
EoE suspension cultures by extraction with Trizol as described by the manufacturer 
(Invitrogen). For every experimental sample, total RNA was quantified both 
spectrophotometrically and electrophoretically, and amounts were adjusted so that 1µg 
was reverse-transcribed (SuperScript reverse transcriptase, Invitrogen). cDNA was 
subjected to PCR (93oC, 30"; 55oC, 30"; 72oC, 30"; 35 cycles) using Taq DNA 
polymerase (Invitrogen) and primer sets derived from rat Fn1 (NM_019143), PKCδ 
(NM_133307), PKCε (NM_017171), PKCη (NM_031085), PKCθ (XM_341553), and 
PKCζ (ΝΜ_022507). Controls were run in the absence of reverse transcriptase. 
GAPDH served as reference standard. 
 
Cell Fractionation 
 MTF7L cells and transfectants thereof were incubated in EoE suspension 
culture in DMEM containing 20% FBS for the indicated periods of time. Cells were 
washed in PBS, collected by centrifugation and resuspended in 0.5 ml ice-cold buffer 
A [50mM Tris (pH 8.0), 150mM NaCl, 1mM EDTA, 1mM EGTA, 1mM NaF, 0.1mM 
NaVO4, 20µM leupeptin, 0.1% aprotinin, and 1mM PMSF]. Cells were disrupted by 
two 15-sec cycles of sonication at 4°C using a microprobe sonicator at maximum 
power. After removal of unbroken cells and nuclei by centrifugation (500xg for 5 min 
at 4°C), supernatants were centrifuged at 16,300xg for 15 min at 4°C. The resulting 
supernatant was designated the cytosolic fraction. The pellet was solubilized in 0.5ml 
buffer A containing 1% Triton X-100 for 1 hour at 4°C EoE, then centrifuged at 
16,300xg for 15 min at 4°C. The detergent-solute was designated the membrane 
fraction. Twenty micrograms of protein from both the cytosolic and membrane 
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fractions were separated by SDS–PAGE (10%), transferred to nitrocellulose 
membrane at 4°C, and probed by Western blotting as described (9). 
 
Cell Lysis, Immunoprecipitation, Western Blotting, and Autoradiography 
 Cells were extracted with lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 
1mM EDTA, 1mM EGTA, 1mM benzamidine chloride, 1mM PMSF, 2 µg/ml 
leupeptin, 0.27 TIU/ml aprotinin, 0.1mM sodium vanadate, and 1% Triton X-100) for 
1h at 4°C (9). Total cell lysates or cytosolic and membrane fractions were subjected 
to: (i) SDS-PAGE (~20-50µg protein) and Western blotting, using anti-Fn[pan], anti-
Fn[EDA], or various PKC isoform specific antibodies, HRP-conjugated  donkey anti-
rabbit or goat anti-mouse secondary antibodies and ECL for detection of bound 
antibody as described (9); (ii) immunoprecipitation with anti-Fn[pan], anti-PKCε or 
anti-PKCδ antibodies (27). Immunoprecipitates obtained from lysates of unlabeled, 
[32P]-orthophosphate-, or [35S]-methionine labeled cells were separated by SDS-PAGE 
(6-12% polyacrylamide) and analyzed by autoradiography (radio-labeled samples) or 
blotted to nitrocellulose membranes and probed with either anti-Fn[pan], anti-
Fn[EDA], anti-PKC isoform-specific antibodies, or anti-pSer and anti-pThr antibodies 
(9).  
 
Tumor Cell Proliferation Assay 
 MTF7L cells and clones thereof were seeded into 96-well microtitration plates 
(500 cells/well) and incubated in DMEM containing 10% FBS. Cell growth was 
monitored in daily intervals for up to 4 days. At the end of each incubation period, 
tumor cells were fixed with 2% paraformaldehyde in PBS and then stained with 0.5% 
crystal violet in 20% methanol as described (21). Absorbance was read on a 
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microplate reader (Bio-Teck Instruments) at 562nm and graphed as a function of time 
of incubation.  
 
Isolation of Blood-Borne Cancer Cells from Tumor-Bearing Rats 
 MTF7L cancer cells (1x106 cells/50µl DMEM) were injected into the 4th 
(left+right) mammary fat pads of six 6-week-old, female Fischer 344 rats. At a tumor 
diameter of ~2cm, rats were anesthetized by the intraperitoneal injection of sodium 
pentobarbital (65mg/kg body weight) and blood collected by cardiac puncture. Pooled, 
EDTA-treated blood was transferred to precooled 50-ml centrifuge trubes containing 
15ml of OncoQuick tumor enrichment medium below a porous barrier (Greiner Bio-
One, Longwood, FL) and centrifuged at 1600g for 20min at 4°C in a swing-out rotor 
as described by Rosenberg et al. (28). After a second round of centrifugation of the 
fluid in the upper compartment, cells were washed with PBS-BSA and stained with 
anti-Fn antibodies as described above. Tumor cells were readily differentiated from 
contaminant blood mononuclear cells by size and intensity of anti-Fn staining in 
comparison with preparations from MTF7L cell-spiked blood.  
 
Lung Colony Assays 
 To determine the effects of Fn- or PKCε-knockdown on the lung colony 
efficiency, selected MTF7L clones as well as wt or vector-transfected MTF7 cells 
(2x105 cells/0.3ml DMEM/rat) were injected into the lateral tail vein of 5-week-old, 
female Fischer344 rats (5-9 rats/experiment) as described (9,21). Rats were sacrificed 
30 days after tumor cell injection. Means and standard deviations of the lung weights, 
the number of lung colonies, and the colony diameters were determined for each cell 
variant (21). 
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RESULTS 
 
Endogenous Fn Is Required for PolyFn Assembly on Suspended Breast Cancer 
Cells 
 Breast cancer cells entering the blood circulation assemble a characteristic 
surface coat of globular polyFn as evidenced by anti-Fn[pan] staining of cancer cells 
isolated from the blood of mammary tumor-bearing rats (Fig 2.1A). This phenomenon 
is mimicked when cancer cells are grown in EoE suspension culture in the presence of 
serum (9). To examine whether polyFn assembly is mediated by exogenous pFn alone 
or whether it critically depends on the synthesis of endogenous cFn, we incubated 
MTF7L breast cancer cells, which express high levels of Fn1 (EDA+EDB+CSIII120), in 
EoE suspension culture in DMEM containing either 20% complete FBS or Fn-free 
fetal bovine serum (FFS). FFS-treated tumor cells stained with either anti-Fn[pan] (Fig 
2.1B) or anti-Fn[EDA] (Fig 2.1B, inset) exhibited similar numbers of polyFn globules 
on their surfaces as FBS-treated cells (Fig 2.1C). However, the addition of complete 
FBS to the suspension medium significantly augmented the size of individual polyFn-
globules relative to those generated by Fn-free FBS (FFS) (Fig 2.1B&C). The serum-
effect on polyFn assembly appeared to be mediated only in part by pFn as shown by 
FACS analysis of MTF7 cells incubated in EoE suspension culture in the presence of  
(i) 20% FBS (Fig 1D&E), (ii) 6µg/ml pFn (amount present in 20% FBS [22]), or (iii) 
20% FFS (Fig 1E). Both 20% FFS and pFn (6µg/ml) were significantly less effective 
in promoting polyFn assembly than FBS (Fig 2.1E). The potency of FFS to promote 
polyFn assembly could be restored to that of FBS by the addition of 6µg/ml pFn (Fig 
2.1E, inset). Thus, FFS appeared to promote surface deposition of cellular Fn (Fn1) on 
suspended MTF7L cells, while pFn in a time- and dose-dependent manner contributed 
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 Figure 2.1:  PolyFn globules expressed on the surface of suspended (blood-borne) 
MTF7L breast cancer cells: (A) MTF7L breast cancer cells were isolated from blood 
of tumor-bearing rats, using the OncoQuick tumor enrichment medium. The 
mononuclear cell fraction separated from red blood cells, platelets, and 
polymorphonuclear leukocyte fractions was washed several times in PBS, then stained 
with rabbit anti-Fn[pan] antibodies followed by PE-conjugated donkey anti-rabbit IgG 
antibodies and observed under a fluorescent microscope. There are multiple Fn 
globules randomly dispersed over the cancer cell surface. (B & C) MTF7L cells 
subjected to EoE suspension culture in DMEM+20% Fn-free FBS (FFS) (B) or 
DMEM+20% complete FBS (C). Both are incubated for 1h at 37°C, then stained as 
described under (A). Notice, the same numerical density of Fn stipples are observed in 
(B) and (C), but a larger stipple size is present in (C) mimicking those observed in (A). 
C-Inset: Same treatment, but stained with anti-Fn[EDA]. (D) FACS analysis of 
MTF7L cells incubated EoE for 1h in DMEM+20% FBS and stained with anti-
Fn[pan] antibodies as described under (A). (E) FACS analysis of MTF7L cells 
incubated EoE for 1h in DMEM+6µg/ml pFn (green), DMEM+20% FFS (red), or 
DMEM+20% FBS (black). Notice that tumor cells treated with DMEM+20% FBS 
(containing ~6µg/ml pFn) exhibit a higher mean fluorescence than tumor cells treated 
with DMEM+20% FFS or DMEM+6µg/ml pFn. E-Inset: Tumor cells incubated with 
20% FFS+6µg/ml (red) and 20% FBS (green) show identical polyFn assembly.  (F) 
FACS analysis of MTF7L cells treated for the indicated periods of time with 
DMEM+20%FBS. There is a time-dependent increase in polyFn assembly. Bars in A-
C: 50µm 
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to augmentation of the Fn polymers by Fn-Fn self assembly (Fig 2.1F).     
To further test the hypothesis that surface deposition of a scaffold of 
endogenous cFn was important for the initiation of polyFn assembly, we examined 
whether inhibitors of protein synthesis (e.g., cycloheximide) (29) or secretion (e.g., 
monensin, Brefeldin A) (30,31) would affect polyFn assembly on suspended MTF7L 
breast cancer cells. Cycloheximide, monensin, and Brefeldin A all dramatically 
impeded polyFn assembly on MTF7L breast cancer cells in the presence of 20% FBS 
(Fig 2.2). Since these compounds might have also impaired surface expression of Fn 
receptors, we used RNA interference to knockdown endogenous cFn in MTF7L (Fn1) 
cells and to examine whether the specific inhibition of MTF7L-cFn would affect 
polyFn assembly. Biochemically, stable clones derived from siRNA-Fn transfected 
cells exhibited a significant decrease in the expression cFn protein as depicted by 
Western blotting (Fig 2.3A; clones cl1 & cl2) and by a dramatic decrease in insoluble, 
metabolically labeled polyFn residing on top of the stack of the polyacrylamide gel 
(Fig 2.3B, clone cl1). Functionally, knockdown of endogenous, cellular Fn was 
associated with impaired surface polyFn assembly on MTF7L cells as shown by 
FACS (Fig 2.3C) and immunocytochemistry (Fig 2.3D&E), albeit all tumor cells were 
incubated in the presence of 20%FBS containing ~6µg/ml pFn. An unspecific 
nucleotide sequences had no affect (Fig 2.3A-E: mclus). Stable siRNA-Fn clones were 
also used to test their lung metastatic potential in lung colony assays. In accordance 
with the level of knockdown of endogenous Fn, lung colonization, assessed by the 
averages of lung weights, colony numbers, and colony diameters, was significantly 
decreased relative to wtMTF7L cells or tumor cells that were stably transfected with 
an unspecific nucleotide sequence (Fig 2.4; siFn-cl1). 
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Figure 2.2:  Inhibitors of protein synthesis and secretion prevent polyFn 
assembly: Adherent MTF7L rat breast cancer cells were exposed for 30 min to 
10µg/ml of cycloheximide (A), 1µM of monensin (B), or 5µM of Brefeldin A (C), 
then subjected to EoE suspension cultured in DMEM+20%FBS in the presence of the 
respective drug or drug solvent (S). After a 1-hr incubation period, cells were stained 
with anti-Fn[pan] antibodies as described in figure 2.1A (control: MTF7L cell stained 
with non-immune rabbit IgG [rIgG]). Tumor cells treated with cycloheximide, 
monensin, and Brefeldin A exhibit a dramatic reduction in the cell surface-associated 
polyFn, relative to those treated with drug solvent. 
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Figure 2.3:  Effect of siRNA knockdown of cFn on polyFn assembly in the 
presence of 20% FBS: Hygromycin-resistant clones were selected from MTF7L 
breast cancer cells transfected with the rat Fn1 nt. sequences #1 (clones cl1 and cl2), rat 
Fn1 nt. sequence #2 (clone cl3), or unspecific nt. sequence #5 (multi-clone mclus) all 
cloned into pRNAU6-Hygro for siRNA targeting as described in Material and 
Methods. (A) Anti-Fn[pan] Western blot from lysates of siFn clones cl1 and cl3, and 
the contol clone mclus. (B) MTF7L cells metabolically labeled with [35S]-methionine 
as described in Material and Methods and ref. 9 were subjected to EoE culture in 
DMEM+20% FBS for 4h, then extracted in lysis buffer containing 1% NP-40 (9). 
Lysates were immunoprecipitated with anti-Fn[pan] and immunoprecipitated proteins 
separated by SDS-PAGE (6%) under non-reducing conditions. Notice the significant 
reduction in the amount of anti-Fn[pan] immunoprecitable material (polyFn) residing 
on top of the stacking gel. (C) FACS analysis of MTF7L siFn clones cl1, cl2, and cl3 
(green) and the control clone mclus (black: control), cultured and stained with anti-
Fn[pan] as described in figure 1A. Mc=mean fluorescence of multi-clone mclus (back); 
MsiFn= mean fluorescence of siFn clones cl1, cl2, and cl3 (green). (D &E) Micrographs 
from MTF7L siRNA-Fn clone cl1 (D) and control-clone mclus (E), both processed and 
stained with anti-Fn[pan] as described in figure 2.1A. Notice a significantly decreased 
polyFn assembly in MTF7L siFn clone cl1 (C), relative to MTF7L control clone mclus 
(D), even though both clones (D&E) were incubated with DMEM+20% FBS for the 
same period of time (1h at 37°C) in EoE suspension culture. Bars in D&E: 50µm. 
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Figure 2.4:  Fn and PKCε siRNA-knockdown inhibit pulmonary metastasis: Cells 
(2x105 cells/0.3ml DMEM/rat) derived from MTF7L clone mclus (control clone), 
clone siFn-cl1 (see Fig 2.3) and MTF7L clone siPKε-cl1 (see Fig 2.8) were injected 
into the lateral tail vein of female Fischer344 rats as described in Material and 
Methods. Numbers of lung colonies were significantly decreased in rats injected with 
MTF7L-siFn-cl1 (*) and, most prominently, with MTF7L-siPKCε-cl1 (*) relative to 
rats injected MTF7L-mclus cells. Colony diameters were reduced by approximately 5-
fold in MTF7L-siFn-cl1 (*) and 2-fold in MTF7L-siPKCε-cl1 relative to MTF7-mclus, 
in which the coalescence of individual colonies to large aggregates might have led to 
an inflated estimate of the colony diameter. [Results presented in this figure may 
reflect to some extent a reduced in vitro growth rate of 29% for MTF7L-siFn-cl1 and 
12% for MTF7L-siPKCε-cl1  cells relative to MTF7-mclus observed after a 4-day 
culture period in vitro].  *, Student’s t-test: p<0.01. 
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PolyFn Assembly Occurs in a PKC-Dependent Manner 
 To identify the signaling cascade that regulates polyFn assembly, we screened 
a diverse group of inhibitors of cell signaling for their ability to impede polyFn 
assembly as determined by routine FACS analyses of anti-Fn[pan] stained MTF7L 
breast cancer cells subjected for 1 hour to EoE suspension culture in FBS (20%)-
containing medium in the presence or absence of inhibitor. These inhibitors included 
pertussis toxin, PD98059, SU6656, PP2, Wortmannin, LY294002, JAKI, and Y27632. 
None of these inhibitors had any effect on the assembly of the polyFn surface coat of 
MTF7L breast cancer cells (data not shown). Consistent with the negative result 
obtained with the ROCK1/2 inhibitor Y27632 is the finding that the Rho activity, 
associated with Fn-matrix assembly and stress fiber formation in adherent cells 
(32,33), steadily decreased during the polyFn assembly phase on suspended breast 
cancer cells. Moreover, transfection with constitutively active Rho (RhoAQ63L) 
suppressed polyFn assembly, while transfection with dominant negative Rho 
(RhoAT19N) appeared to promote polyFn assembly (Cheng and Pauli, manuscript in 
preparation). In contrast, polyFn assembly was dramatically reduced by U73122, an 
inhibitor of phospholipase C (PLC) (34) and the PKC inhibitor calphostin C, which 
competes with the diacylglyceral and phorbol ester binding site of conventional PKCs 
(cPKCs) and nPKCs (35) (Fig 2.5A). Together, these findings suggest involvement of  
a cPKC or nPKC isoform, but not an atypical PKC (aPKC) isoform, presumably 
acting downstream of PLC in polyFn assembly on MTF7L cancer cell surfaces (36).  
 
PKCε Is the Mediator of polyFn Assembly and Metastasis 
 Our attempts to identify the PKC isoform responsible for polyFn assembly 
were preceded by determining the c- and nPKC expression levels in MTF7L breast 
cancer cells. As reported for adherent, metastatic MT tumor variants by Kiley et al. 
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Figure 2.5:  Inhibitors of PLC and PKC diminish polyFn assembly: (A) MTF7L 
breast cancer cells were incubated in the presence of U73122 (PLC inhibitor) and 
calphostin C (inhibitor of cPKCs and nPKCs) at the indicated concentrations or 
inhibitor solute (DMSO, control) for 30min, then subjected to EoE suspension culture 
for 1h in DMEM+20%FBS+inhibitor (or inhibitor solute [S]). Cells were then stained 
for Fn surface expression as described in figure 2.1A and analyzed by FACS (negative 
control: cells stained with non-immune rabbit IgG). Strong, dose-dependant inhibition 
of polyFn assembly was observed with both U73122 and calphostin C. (B) Expression 
of c- and nPKC isoforms in MTF7L cells: MTF7L breast cancer cells were subjected 
to EoE suspension culture for 1h in DMEM+20%FBS. One half of the cells were 
extracted with Trizol and RNA purified as described by the manufacturer (Invitrogen), 
the other half was extracted with lysis buffer. One microgram of purified RNA was 
subjected to RT-PCR (35 cycles) using PKC isoform-specific primers (upper panel). 
GAPDH served as reference message. Controls were samples run in the absence of 
reverse transcriptase (RTase). Cell lysates were subjected to SDS-PAGE and Western 
blotting with isoform-specific anti-PKC antibodies (lower panel). Strong message 
levels were recorded for PKCα, δ, and ε, moderate for PKCη, and weak for PKCθ. 
Protein expression was strong for PKCα, δ, and ε, weak for PKCη, and non-detectable 
for PKCθ.  
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 (37), suspended MTF7L cells strongly express PKCα, PKCδ, and PKCε, both at the 
mRNA and protein levels (Fig 2.5B). PKCη mRNA is expressed moderately and 
protein weakly, and PKCθ mRNA weakly and protein non-detectably (Fig 2.5B). 
Next, we used select PKC inhibitors to narrow the spectrum of PKC isoforms involved 
in polyFn assembly. Failure of high doses of the cPKC inhibitors Gö6976 and 
HBDDE (38) to prevent polyFn assembly ruled out participation of PKCα in polyFn 
assembly (Fig 2.6A). In contrast, inhibitors that in addition to cPKCs also inhibited 
nPKCs, including BIM I, Gö6983, BIM XI (Ro-32-0432), and Rottlerin (39-43), 
decreased polyFn assembly in dose-dependant manners (Fig 2.6B). Albeit these 
inhibitor data do not provide conclusive evidence of the nPKC isoform involved in 
polyFn assembly, PKCδ (preferentially, but not specifically, inhibited by Rottlerin, 
ref. 43) and PKCε (preferentially inhibited by BIM XI) are our most likely candidates 
for involvement in polyFn assembly based on high protein expression levels and 
inhibitor activity. 
 To examine the roles of PKCδ, PKCε and PKCη (nPKC isoforms previously 
associated with breast cancer metastasis, see refs. 44-46) in polyFn assembly, we 
transfected MTF7L cells with the regulatory domains (RD) of these isoforms or 
knocked down their expression by PKC isoform-specific siRNA oligonucleotides.  
The RD domains of PKCδ (co-transfected with GFP at a ratio of 1:50), PKCη-GFP 
and PKCε-GFP were transiently expressed in MTF7L breast cancer cells. Forty-eight 
hours after transfection, cancer cells were subjected to EoE suspension culture in 
serum-containing medium for 1 hour, then stained with anti-Fn antibodies, and Fn 
visualized by PE-conjugated secondary antibodies. Cells were analyzed by bivariate, 
dual-color (red-green) FACS. Among the three nPKC isoforms, only RD-PKCε 
inhibited polyFn assembly as depicted by a significant down-shift in the number of 
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Figure 2.6: Effect of various PKC inhibitors on polyFn assembly: (A) Inhibitors of 
cPKCs such as Gö6976 and HBDDE have no effect on polyFn assembly.  (B) 
However, other PKC inhibitors such as BIM I, BIM XI, Gö6983, and Rottlerin inhibit 
polyFn assembly in a dose-dependant manner. Experiments were conducted as 
described in figure 2.5A. Significant differences in polyFn assembly by BIM XI at 
100nM and 500nM and Rottlerin at 3µM and, more notably, at 100µM provide strong 
clues of a possible involvement of PKCε or PKCδ, given the fact that these isoforms 
are also strongly expressed in suspended MTF7L cells. S, drug solvent. 
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GFP-positive cells that strongly stained with anti-Fn antibody, i.e., only 21% of tumor 
cells that expressed high levels of GFP also expressed high levels of polyFn, relative 
to 56% in vector transfected cells (Fig 2.7A). The RD sequences of PKCη had no 
effect on polyFn assembly, while the RD sequence of PKCδ caused an increase in the 
number of strongly GFP-positive cells that expressed high levels of polyFn (Fig 2.7A), 
suggesting that PKCδ might exert a negative regulatory role in polyFn assembly.  
 A similar effect on polyFn assembly to that of RD-PKCδ and RD-PKCε was 
observed when MTF7L cells were co-transfected transiently with GFP and siRNA-
PKCδ or siRNA-PKCε and subjected to bivariate FACS analyses 48h or 72h after 
transfection. Again, knockdown of PKCε suppressed polyFn assembly, while 
knockdown of PKCδ resulted in increased polyFn assembly on MTF7L cell surfaces 
(Fig 2.7B). These results were confirmed by the analysis of stable MTF7L clones with 
“siRNA-knockdown” of PKCε. PKCε-knockdown resulted in a significant decrease in 
polyFn assembly relative to a control clone transfected with an unspecific siRNA 
nucleotide sequence (Fig 2.8A). As expected, the FACS-measured decrease in polyFn 
paralleled decreased PKCε protein expression (Fig 2.8B) as well as decreased amounts 
of polyFn residing on top of the stack of polyacrylamide gels (Fig 2.8C, top), 
generated from anti-Fn[pan]-immunoprecipitates of metabolically labeled siRNA-
PKCε and control clones. The biochemically identified decrease in polyFn was 
reflected in decreased surface-association of polyFn on MTF7L cells stained with anti-
Fn[pan] (Fig 2.8C, bottom). Functionally, impaired polyFn assembly in siRNA-PKCε 
clones is associated with a dramatic decrease in lung colonization (Fig 2.4).  
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Figure 2.7: (A) Effect of RD-PKCδ, RD-PCη, and RD-PKCε on polyFn assembly: 
MTF7L breast cancer cells grown to a density of 70-80% were transiently transfected 
with the regulatory domains (RD) of PKCδ, PKCη, and PKCε as described in Material 
and Methods. Forty-eight hours after transfection, cells were subjected to EoE 
suspension culture in DMEM+20%FBS for 1h at 37°C, then stained with anti-Fn[pan] 
antibodies as described in Figure 2.1A and immediately analyzed by bivariate, dual-
color [red fluorescence (FnF) vs. green fluorescence (GF)] FACS. Gates were selected 
based on the staining of wtMTF7L cells with non-immune rabbit IgG and Fn staining 
of vector-transfected MTF7L cells. Cells in the upper right quadrant of the scatter 
gram (=strong expressers of RD-PKC and Fn) were expressed as percent of the sum of 
cells in the right upper and lower quadrants (=strong RD-PKC expressers: gray area), 
thereby providing a quantitative measure of the inhibitory activity of each RD-PKC 
isoform on polyFn assembly. Data show inhibitory activity of RD-PKCε, stimulatory 
activity of RD-PKCδ, and no effect of RD-PKCη. (B) Effect of PKCδ and PKCε 
siRNA-knockdown on polyFn assembly: MTF7L breast cancer cells grown to a 
density of 70-80% were transiently co-transfected with either pRNAU6-Hygro-
siRNA-PKCε (sequence #3), pKD™-PKCδ-v6, or pRNAU6-Hygro-siRNA-us 
(unspecific nt. sequence #5) and GFP at a cDNA ratio of 50:1 as described in Material 
and Methods. Forty-eight hours after transfection, tumor cells were analyzed by 
FACS. Using a similar gate setting as in (A) [MTF7L cells stained with non-immune 
rabbit IgG and MTF7L cells transfected with siRNA-us and stained with anti-Fn[pan] 
antibodies], only 33% of the siPKCε-transfectants exceeded the ~50% threshold in 
polyFn assembly of siRNA-US transfectants, while in siPKCδ-transfectants this value 
was 73%. Fn-F, Fn fluorescence; GFP-F, GFP fluorescence.  
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Figure 2.8: Analysis of stable clones selected from siRNA-PKCε transfected 
MTF7L cells:  siRNA-PKCε clones (cl1 and -cl2) were hygomycin-selected from 
MTF7L cells transfected with the nt. sequence #3, siRNA-PKCε-cl3 from MTF7L 
cells transfected with the nt. sequence #4, andcontrol clone mclus from MTF7L cells 
transfected with the unspecific nt. sequence #5 [see Material and Methods]: (A) 
Clones PKCε-cl1 and -cl2 and control clone mclus subjected to EoE suspension culture 
in DMEM+20% FBS for 1h were stained with anti-Fn[pan] and analyzed by FACS as 
described in Material and Methods, then analyzed by FACS. PolyFn assembly by 
MTF7L clones PKCε-cl1 and PKCε-cl2 was significantly decreased relative to the 
mclus control clone. (B) Western blot analysis for PKCε− and vinculin-expression in 
lysates from siPKCε-cl1, -cl2 and -cl3 and the mclus clone: PKCε protein is decreased 
in siPKCε clones relative to the unspecific siRNA-mclus control clone. (C) Lysates 
from MTF7L clones mclus and siPKCε-cl1 labeled with [35S]-methionine and 
processed as described in Fig 2.3B were subjected to anti-Fn[pan]-
immunoprecipitation followed by SDS-PAGE and autoradiography. There is a 
significant decreased in polyFn residing on top of the stacking gel in siPKCε-cl1 
relative to the mclus control, mimicking the degree of tumor cell surface-associated 
polyFn of these clones stained with anti-Fn[pan] (C, bottom). 
 
 
 
 
 
78 
 
 
 
 
 
 
 
 
79 
 
Plasma Membrane Translocation and Activation of PKCε Promote and PMA 
Suppresses polyFn Assembly 
 The process of polyFn assembly was associated with a time-dependent 
translocation of PKCε to the plasma membrane. In adherent MTF7L cells, PKCε was 
present predominantly in the cytosolic fraction (Fig 2.9A: Time 0), but translocated in 
increasing amounts to the plasma membrane when MTF7L cells were subjected to 
EoE suspension culture in the presence of pFn-containing serum (Fig 2.9A: Time 15-
60 min). Peak values for membrane-associated PKCε were observed at 30 min of 
incubation in EoE suspension culture and remained high for the remainder of the 1h 
incubation period. Translocation of PKCε to the plasma membrane was associated 
with a noticeable gain of its molecular weight, presumably caused by the observed 
serine- and threonine phosphorylation of PKCε. PKCε phosphorylation, again, was 
most prominent at 30 min of EoE suspension culture, then rapidly declined to barely 
detectable levels at 60 min (Fig 2.9B). This decline was accompanied with a backward 
shift to the lower molecular weight form of PKCε (Fig 2.9A). The PKC inhibitor BIM 
XI totally blocked PKCε phosphorylation (Fig 2.9B). This result was confirmed when 
32P-labeled MTF7L were examined for PKCε-phosphorylation (Fig 2.9C). Control 
experiments conducted with PKCδ yielded no phoshorylation of this PKC isoform 
(Fig 2.9D). Interestingly, PMA (1µM) caused a time-dependent loss of PKCε protein 
from both the cytosolic and membrane fractions of MTF7L cells (Fig 2.10A). The 
PMA-mediated loss of PKCε protein, and to a slightly lesser extent of PKCδ protein, 
was most striking after an 18h incubation period of tumor cells with PMA. No effect 
was observed for the PMA-insensitive aPKC isoform PKCζ (Fig 2.10B). 
Concomitantly, loss of PKCε protein and decreased plasma membrane translocation in 
PMA-treated cells resulted in a dose-dependent, diminished polyFn assembly (Fig 
2.10C).  
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Figure 2.9:  Membrane translocation and phosphorylation of PKCε: (A) PKCε 
translocates in increasing amounts from the cytosol to the plasma membrane during 0, 
15, 30, and 60 min of EoE suspension culture of MTF7L in DMEM+20% FBS. Notice 
a slightly higher molecular weight of PKCε harvested from the membrane fraction 
(M) relative to that from the cytosolic fractions (C). (B) Time course of PKCε 
phosphorylation: MTF7L were incubated in EoE suspension culture for the indicated 
periods of time in DMEM+20% FBS in the presence or absence of BIM XI (500nM). 
At the end of the indicated time periods, cells were lysed, and lysates subjected to anti-
PKCε immunoprecipitation. Precipitates were probed by Western blotting with anti-
PKCε, anti-pSer, and anti-pThr antibodies. Maximal phosphorylation of PKCε was 
observed at 30 min of EoE suspension culture. Thereafter, the PKCε phosphorylation 
decreased to barely detectable levels at 60 min. PKCε of MTF7 cells treated with BIM 
XI stained weakly or non-detectably with anti-pSer and anti-pThr. (C & D) [32P]-
incorporation into PKCε (C) and PKCδ (D):  MTF7 cells labeled for 4h in phosphate-
free DMEM containing 100µCi/ml of [32P]orthophosphate as described in Material 
and Methods were subjected for 30min to EoE suspension cultures in 
DMEM+20µg/ml pFn (lane 2), DMEM+20%FBS (lane 3), and 
DMEM+20%FBS+500nM BIM XI (lane 4) [control: [32P]orthophosphate-labeled, 
adherent cells incubated for 30min in DMEM+20%FBS (lane 1)]. Anti-PKCε  (C) and 
anti-PKCδ (D) immunoprecipitates were analyzed by autoradiography. RG, 
radiograph; WB, Western blot; IP, immunoprecipitation. 
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Figure 2.10: Effect of PMA on PKCε and polyFn assembly: (A) PMA treatment 
(1µM) of MTF7L cells caused a time-dependent loss of PKCε from both cytosolic and 
membrane fractions relative to untreated cells, in which PKCε decreased in the 
cytosolic fraction, but increased in the membrane fraction with time of incubation. (B) 
MTF7L cells pretreated with 1µM PMA for 18h, then subjected to EoE suspension 
culture in DMEM+20%FBS+1µM PMA exhibited decreased amounts of PKCδ 
protein and, particularly, PKCε protein relative to cells treated without PMA, while 
protein expression of the atypical PKC isoform PKCζ was unaffected by PMA 
(control). (C) PMA caused a dose-dependent decrease in polyFn assembly on MTF7L 
cells subjected to EoE suspension culture in DMEM+20%FBS for 1h. (S=PMA 
solvent).   
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DISCUSSION 
 
 The role of Fn in cancer progression is controversial. Early studies suggest that 
Fn may act as a tumor suppressor gene, promoting differentiation and suppressing 
proliferation, migration, invasion, and metastasis (reviewed in refs. 13-16). In 
accordance, expression of pFn in Fn-negative LMM3 murine mammary cancer cells 
reduced the rate of migration as well as spontaneous and experimental metastasis (47), 
and forced expression of the α5β1 integrin, which was thought to capture secreted cFn 
at the cell surface, convert it into fibrils and then deposit it in the extracellular matrix, 
reduced motility and tumorigenicity of transfected tumor cells (48). These findings are 
contrasted by cDNA or oligonucleotide microarray analyses that attempted to identify 
genes whose expression was associated with malignant behavior of breast cancers. In 
several of these studies, Fn (Fn1: EDA+EDB+IIICS120) was found to be consistently 
overexpressed in invasive/metastatic breast tumors in toto as well as in tumor cells 
isolated by laser capture microdissection from a primary invasive ductal carcinoma 
and an axillary node harboring metastatic breast cancer (5-7). Interestingly, ErbB2 
overexpression, observed in 25-30% of invasive ductal breast carcinomas and 
correlated with a poor clinical prognosis, was associated with Fn1 overexpression in 
11 out of 36 cases (49). Overexpression of Fn was also noticed in cancer cell lines that 
exhibited an invasive/metastatic phenotype, including MDA-MB-231, MeWo-70W, 
PC3-ML, 4T1, LLC1, B16-F10, K7M2, MTF7, and RPC-2 (17), and was most 
dramatic in cancer cell lines that were subjected to a selection process for enhanced 
lung metastatic performance (9,11,17) or in highly metastatic clones derived from a 
rabdomyosarcoma (8) or B16 melanoma (10), but not in non-metastatic clones (8). 
Moreover, expression of the metastasis suppressor gene nm23 in MDA-MB-435 breast 
cancer cells resulted in a down regulation of genes associated with adhesion and 
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motility, including Fn1 (50). On the other hand, neither the poor prognosis signature 
obtained by large-scale transcript profiling of human breast cancers (51,52) nor the 
gene expression profile that was associated with lung-metastasis of selected MDA-
MB-231 clones (i.e., lung-metastatic signature) contained Fn (53). A possible 
explanation for this result may be related to the multi-functional role of Fn in tumor 
progression, requiring high levels of Fn expression throughout tumor progression. For 
example, in early stages of progression Fn promotes survival, cell cycle progression, 
and angiogenesis and in later stages motility/invasiveness and dissemination and 
implantation in secondary organs (reviewed in refs. 12-16). Support for this notion can 
be found in the observation that tumor cell lines that do not express Fn such as MCF-7 
cells exhibit poor tumorigenicity, growth, and angiogenesis (54), while 
overexpresssion of c-Jun in MCF7 cells stimulated Fn synthesis and, concomitantly, 
increased tumorigenicity and invasiveness (55,56). 
 In recent years our laboratory has been interested in the role of Fn in breast 
cancer lung metastasis. This interest was triggered by the fact that a survey of all our 
highly lung-metastatic breast cancer cell lines, including MTF7, MTF7L, MDA-MD-
231 and 4T1 cells, revealed high levels of Fn expression (17) and by the observation 
that tumor cells isolated from the blood of tumor-bearing animals exhibited a 
characteristic cell surface coat of multi-globular polyFn. This phenotype could be 
reproduced in vitro, when cancer cells were subjected to EoE suspension culture in the 
presence of serum (9,17). As indicated in the introduction, this unique surface 
expression of Fn was responsible for the docking of MTF7 to the lung endothelial 
addressin DPP IV (9,17-21) and for facilitating lung colonization (9,17,20,21). 
Interference with the polyFn/DPP IV adhesion by monoclonal antibodies (9), peptides 
directed against the DPP IV-binding domains in the 13th, 14th and 15th type III repeats 
of Fn (17), and a polypeptide representing the extracellular domain of DPP IV (20) 
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abrogated metastatic colonization of the lungs. Here, we have presented some of the 
molecular underpinnings that regulate polyFn assembly in a rat model of 
hematogenous dissemination of breast cancer cells. We show that polyFn assembly 
critically depends upon the expression of endogenous cFn (Fn1) and is regulated by 
PKCε. This is evidenced by a significantly decreased polyFn assembly in cells 
transfected with either siRNA-PKCε or dominant-negative RD-PKCε, and in cells 
treated with select PKC inhibitors. During a 1-hour polyFn assembly phase, PKCε 
translocates in increasing amounts from the cytosol to the plasma membrane. This 
translocation is accompanied by PKCε Ser/Thr-phosphorylation and is crucial for 
successful polyFn assembly, since overexpression of dominant-negative RD-PKCε, 
which blocks DAG-mediated plasma membrane-docking and activation of 
endogenous PKCε (57,58), prevents polyFn assembly. In contrast, both RD-PKCδ and 
siRNA knockdown of PKCδ promoted polyFn assembly, mimicking the previously 
recognized opposing effects of PKCε and PKCδ in ischemic injury of the heart (59) 
and suggesting a dominant-negative regulatory effect of PKCδ over PKCε in MTF7L 
cells. A PKCε regulatory effect was also observed for PMA, which in a dose- and 
time-dependent manner inhibited PKCε protein synthesis and, in accordance, impaired 
polyFn assembly on MTF7L cells in a manner similar to that reported for other cell-
types (60,61). Together, PMA/DAG competition for plasma membrane-docking, 
overall loss of PKCε protein, and competition between related PKC isoforms appear to 
be primarily responsible for the observed decrease in polyFn assembly on cancer cell 
surfaces.  
 The role of PKCε in polyFn assembly appears to be dualistic in that it may 
facilitate surface expression of endogenous, cellular Fn by promoting Fn exocytosis 
(62-66) and protein synthesis (67). In accordance, inhibitors of protein synthesis (e.g., 
cycloheximide) and exocytosis (e.g., monensin and Brefeldin B) strongly impeded 
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polyFn assembly (Fig 2), albeit cells were kept in suspension culture in the presence of 
high concentrations of pFn.  However, at this writing we have not identified any of the 
PKCε partner proteins that are required in regulating these processes. Nonetheless, 
inhibition of PKCε has been shown to trap integrin β1, a possible receptor for cellular 
Fn, in a CD81-positive intracellular compartment and electron microscopy 
demonstrated the co-localization of PKCε and integrin β1 on vesicular membranes 
(68). Translocation of the integrin β1 from cytosolic vesicles to the plasma membrane 
appears to involve the PKCε-mediated phosphorylation of the cytoplasmic tail of β1-
integrin at threonine 788/789 (69) or cytoskeletal intermediaries such as vimentin (70) 
and actin (62). Accordingly, interaction of PKCε with actin has been linked to the 
formation of invadopodia-like structures, increased pericellular metalloproteinase 
activity and, ultimately, invasiveness and metastasis in PKCε-transformed NIH3T3 
fibroblasts (71). Whether the concomitant downregulation of RhoC in MDA-MB-231 
cells, in which PKCε expression was knocked down by RNA interference resulting in 
a cell phenotype that was significantly less proliferative, invasive, and metastatic (45), 
is intertwined in PKCε-actin remodeling is unclear and needs further investigation. 
Supporting evidence for such role may be deduced from the thrombin-induced PKCε-
Rho-actin complex formation in actin reorganization in myofibroblasts (72). However, 
in our system of suspended (blood-borne) breast cancer cells, the Rho activity is 
significantly suppressed and expression of constitutively active Rho suppresses 
polyFn assembly (Cheng and Pauli, manuscript in preparation). 
 In conclusion, our studies suggest that surface expression of polyFn occurs in 
PKCε-dependant manner presumably involving the transport of Fn-receptor 
complexes from cytosolic vesicles to the plasma membrane and that such complexes 
serve as scaffolds for the subsequent augmentation of polyFn aggregates on tumor 
cells during their journey in Fn-rich blood plasma. This notion is supported by a 
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dramatic inhibition of polyFn assembly by inhibitors of exocytosis and by siRNA-
knockdown of PKCε, that occurs even when cancer cells are exposed to high 
exogenous Fn concentrations and express several integrin and syndecan Fn-receptors 
on their surfaces (Cheng, unpublished data). Thus, we have disclosed here a novel 
regulatory principle for the recognized  “pro-metastatic” role of Fn that may spur the 
design of new anti-metastatic therapies. 
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CHAPTER III 
 
POLYMERIC FIBRONECTIN ASSEMBLY ON THE SURFACE OF BREAST 
CANCER CELLS IS DEPENDENT ON SUBCELLULAR LOCALIZATION OF 
PKC ΕPSILON-ACTIN COMPLEX AND PYK2 ACTIVITY* 
 
 
 
 
 
 
 
 
 
*    Huang L, Pauli BU. Polymeric fibronectin assembly on the surface of breast 
cancer cells is dependent on subcellular localization of PKCε-actin complex and 
PYK2 activity. To be submitted to Experimental Cell Research. 
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ABSTRACT 
 
 Lung colonization by breast cancer cells is mediated, at least in part, by 
interaction of lung endothelial dipeptidyl-peptidase IV (DPPIV; CD26) with breast 
cancer cell surface polymeric fibronectin (polyFn). PolyFn on the surface of MTF7L 
rat breast cancer cells has been shown previously to be regulated by protein kinase C 
epsilon (PKCε). Here, we introduce β-actin and proline-rich tyrosine kinase-2 (Pyk-2) 
as partners of PKCε in orchestrating the successful polyFn assembly on MTF7L cells. 
Mimicking conditions of cancer cells disseminating in the blood, MTF7L cells 
subjected to end-over-end suspension culture exhibit an increasing accumulation of 
PKCε and F-actin in the subplasmalemmal space beneath emerging polyFn surface 
aggregates. Translocation of these proteins and polyFn assembly is abrogated by 
Cytochalasin D, an actin barbed-end capping drug, and to a lesser extent latrunculin B, 
an actin monomer sequestering drug. PKCε-actin interaction is dependent on PKCε 
catalytic activity, as shown by treatment of suspended cancer cells with the PKCε 
inhibitor bisindolylmaleimide XI (BIMXI; Ro-32-0432), but does not involve the 
unique PKCε actin binding domain. Catalytic activity of Pyk2 is required for 
successful assembly of polyFn, as shown by the absence of polyFn assembly upon 
transfection of cancer cells with kinase dead Pyk2. The present study provides new 
insights into the regulation of the PKCε-mediated polyFn assembly and pulmonary 
metastasis of breast cancer cells that may harbor new therapeutic potentials.  
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INTRODUCTION 
 
 Cancer cells isolated from blood of rats or mice from malignant breast tumors 
implanted into the mammary fat pad are adorned with a multi-globular coat of 
polymeric fibronectin (polyFn) (1). These polyFn aggregates increase in size with time 
of incubation in suspension and assemble into increasingly deoxycholate-insoluble 
polymers that can be seen in the top of the stacks of SDS-polyacrylamide gels (1) and 
on the surface of cancer cells with immunofluorescent staining. Conversion of Fn from 
the globular (soluble) to the linearized state (insoluble, surface-associated) exposes a 
cryptic domain in Fn responsible for binding to DPPIV on lung endothelial cells. The 
DPPIV domain of Fn has been identified as a consensus motif in each of the 13th, 14th 
and 15th type III repeats of Fn. DPPIV binding is specific for the linearized form of Fn 
and not for the globular form, facilitating cancer cell adhesion in the presence of high 
Fn concentrations in the plasma under physiological conditions (1). The cluster 
arrangement of polyFn aggregates presents multiple binding sites for interaction with 
DPPIV that strengthens cancer cell and endothelial cell adhesion and enables cancer 
cell vascular arrest under hemodynamic shear stress (1). These findings are consistent 
with our studies with rodent models showing reduced lung colonization in Fischer 
344/CRJ rats with mutated DPPIV and diminished pulmonary endothelia expression 
(2) and in DPPIV-/- mice (3).  
We have recently elucidated one of the PKCs responsible in mediating polyFn 
assembly on breast cancer cells. In the rat model of hematogenous dissemination of 
breast cancer cells, polyFn assembly and lung metastasis critically depends on 
expression of endogenous cellular Fn (cFn) and is regulated by PKCε (4). 
Pharmacological inhibition, expression of dominant negative forms of PKCε and 
knockdown of PKCε lead to decreases in the levels of polyFn on cancer cell surface 
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and lung colonization (4). Several possible pathways may account for the ability of 
PKCε to mediate polyFn formation. PKCε may regulate polyFn assembly on the cell 
surface by phosphorylation of cytoskeletal regulators, through signaling to other 
signaling pathways and/or control extracellular matrix receptors (5-11). To promote 
substrate recognition, PKC may directly interact with its substrates (substrates that 
interact with C-kinase, STICK) or bind to proteins that facilitate substrate 
phosphorylation (receptors for activated C-kinase, RACK). STICKs localize to a range 
of specific cellular compartments which includes plasma membrane, cortical 
cytoskeleton, focal contacts, nucleus and vesicles (5) and allow PKC to perform 
specialized function. Several PKC substrates, such as myristoylated alanine-rich 
protein kinase C substrate (MARCKS), have a role of anchoring the actin cytoskeleton 
to the plasma membrane (6). On the other hand, PKCε may also directly 
phosphorylate kinases that are able to activate polyFn receptors. PKCε has been 
shown to play a role in the activation of Pyk2 (7), which is able to bind the 
phosphorylated integrin beta3 cytoplasmic tail (8) and promote integrin ligand binding 
ability. Lastly, PKCε may control integrin function. PKCε is involved in inside-out 
signaling for beta integrin mediated cell adhesion (9-11) and RACK1 has been shown 
to be one of the mediators of binding between integrin beta chains and PKCε. Whether 
direct or indirect, integrin activation may indeed be an important pathway in PKCε-
mediate polyFn assembly remains to be seen. 
In order to further elucidate the role of PKCε in polyFn assembly, we have 
utilized matrix-assisted laser desorption/ionization time of flight mass spectrometry 
(MALDI TOF/ m/s) fingerprinting to identify proteins that reside in the PKCε 
complex under cancer cell-activating conditions. Two cytoskeletal proteins, β-actin, 
cytoplasmic-2 and myosin IIa (Myh9) have been identified in PKCε 
immunoprecipitates. Focusing on the contribution of β-actin-2, we report that polyFn 
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assembly is dependent on PKCε/actin interaction and cytoskeletal integrity. With time 
of incubation of cancer cell in suspension, PKCε and F-actin translocated in increasing 
amounts in the subplasmalemmal space at the base of globular polyFn aggregates. 
This translocation is associated with activation and phosphorylation of Pyk2. 
Disruption of the PKCε/actin association by actin polymerization blocking agents such 
as Cytochalasin D and kinase-dead Pyk2 prevent polyFn assembly. Together, our 
study presents a role of PKCε in the regulation of polyFn assembly through interaction 
with the actin cytoskeleton and activation of Pyk2.   
 
MATERIAL AND METHODS 
 
Antibodies and Reagents   
 Rabbit and mouse anti-PKCε polyclonal antibody and mouse anti-βactin 
antibody for western blotting were from Santa Cruz Biotechnology (Santa Cruz, CA), 
rabbit anti-Fn polyclonal antibodies that recognized pFn and cFn from both bovine 
and rat (anti-Fn[pan]: does not crossreact with fibrinogen,  vitronectin, laminin, 
collagen type IV) were from Sigma (St. Louis, MO), mouse anti-PKCε used for 
immunoprecipitation was from BD Biosciences (San Jose, CA), phycoerythrin (PE)-
conjugated donkey anti-rabbit, horseradish-peroxidase (HRP)-conjugated  donkey 
anti-rabbit, and HRP-conjugated goat anti-mouse antibodies were from Jackson 
ImmunoResearch (West Grove, PA), rabbit anti-Pyk2 antibody werefrom Upstate 
(Lake Placid, NY), and phospho-specific anti-Pyk2(Tyr402) were from Cell Signaling 
(Danvers, MA). PKC inhibitor BIM XI (Ro-32-0432) was from EMD Chemicals (San 
Diego, CA). Actin inhibitor Cytochalasin D and Latrunculin B was from Sigma (St. 
Louis, MO). Fetal bovine serum (FBS) was purchased from Gemini Bio-Products 
(Woodland, CA). All other chemicals and reagents were from Sigma. 
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Cell Cultures   
 MTF7L cells were derived from a lung-metastasis generated by tail-vein 
injection of MTF7 breast cancer cells (obtained from Dr. D.R. Welch, University of 
Alabama at Birmingham, Birmingham, AL) into Fischer 344 rats. At an i.v. 
inoculation dose of 2x105cells/0.3ml PBS per rat, MTF7L cells consistently produce 
in excess of 400 lung colonies. Cells were grown in culture in Dulbecco’s Modified 
Eagle Medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS). 
For end-over-end (EoE) suspension culture, MTF7L cells were grown to 80 to 90% 
confluence, then removed from the growth surface by trypsinization [0.25% trypsin, 
0.02% EDTA in phosphate-buffered saline (PBS); 10 min, 37°C], washed twice in 
DMEM containing 10% FBS, and subjected to EoE suspension culture for 1 hour (or 
as indicated) in 2ml-centrifuge tubes in DMEM plus 20% FBS at a concentration of 
5x106 cells/ml (1,13). Tumor cells were used for all experiments within 10 passages 
from frozen stocks that were tested for metastatic performance immediately prior to 
freezing. 
 
Plasmids Constructs, Transfection, and Selection 
 The construct Wild type PKCε (PKCε−WT) cloned into pEGFP-N1 was 
obtained from Dr. C. Larsson (Lund University, Malmö, Sweden) (12). PKCε with 
actin binding domain 223-228 deleted (PKCε−ΔABDε) was constructed from 
PKCε−WT  using Quickchange XL Site-directed mutagenesis kit from Stratagene (La 
Jolla, CA). Wild type FAK, kinase dead FAK (K454R), wild type Pyk2 and kinase 
dead Pyk2 (K457R) cloned into pKH3 vector were obtained from Dr. Jun-Lin Guan 
(Cornell University, Ithaca, NY). All plasmid constructs were verified by double-
stranded sequencing. 
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 MTF7L cells grown to 70% confluence were transiently transfected with above 
vector constructs or vector alone using ExGen 500 (Fermentas, Glen Burnie, MD) as 
described by the manufacturer. Transfection rates were assessed by expression of GFP 
that is either tagged to the cDNA of interest or co-transfected at a ratio of 1:50 with 
the cDNA of interest, which were 30-40 %. Cells were used in the various assays 24h 
after transfection unless otherwise stated.  
 
Flow Cytometry 
 FACS was used to quantify Fn expression on MTF7L breast cancer cell 
surfaces (1, 13). Tumor cells that had been subjected to EoE suspension culture were 
washed twice in DMEM containing 1% bovine serum albumin (BSA), then incubated 
with rabbit anti-Fn[pan] antibody diluted 1:100 in PBS containing 1%BSA (PBS-
BSA) for 1h at 4°C. After washing in PBS-BSA, tumor cells were stained with 
phycoerythrin (PE)-conjugated donkey anti-rabbit antiserum in PBS-BSA for 1h at 
4°C and fixed in 2% paraformaldehyde in PBS. FACS analysis was performed on a 
Coulter Epics Profile (Coulter Electronics, Hialeah, FL). Nonspecific fluorescence 
was accounted for by incubating tumor cells with non-immune rabbit serum instead of 
primary antibody. To quantify the effect of overexpressed proteins on polyFn 
assembly, we generate bivariate distributions of red fluorescence (y-axis: cells stained 
with anti-Fn antibodies and PE-conjugated secondary antibodies) and green 
fluorescence (x-axis: same cells expressing GFP-tagged protein or co-transfected with 
GFP and cDNA of interest). The levels of polyFn expression in the cell population 
that emitted high GFP fluorescence were taken as a reflection of the effect of the 
transfected cDNA on polyFn assembly. X-axis gates were selected based on the 
staining of MTF7L cells with non-immune rabbit IgG. Y-axis gates were selected 
based on 50% Fn staining intensity of the vector transfected GFP-positive cells. Cells 
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in the upper right quadrant of the scatter gram (strong expressers of PKCε and Fn) 
were expressed as percent of the sum of cells in the right upper and lower quadrants 
(strong PKCε expressers), providing a quantitative measure of the inhibitory activity 
of transfected plasmids or pharmacological inhibitors. To assess the effect of 
inhibitors of cell signaling, tumor cells were incubated with inhibitor 30-min prior to 
and throughout EoE suspension culture in DME/FBS, then subjected to polyFn 
quantification as described above. Controls were tumor cells incubated in equimolar 
inhibitor solvent concentration. 
 
Cell Lysis, Immunoprecipitation, and Western Blotting 
 Cells were extracted with lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 
1mM EDTA, 1mM EGTA, 1mM benzamidine chloride, 1mM PMSF, 2 µg/ml 
leupeptin, 0.27 TIU/ml aprotinin, 0.1mM sodium vanadate, and 1% Triton X-100) for 
1h at 4°C (9). Total cell lysates were subjected to: (i) SDS-PAGE (~20-50µg protein) 
and Western blotting, using anti-Fn[pan], anti-PKCε, anti-PYK2, phospho-specific 
anti-PYK2 antibodies, anti-β-actin, HRP-conjugated  donkey anti-rabbit or goat anti-
mouse secondary antibodies and ECL for detection of bound antibody as described 
(1); (ii) immunoprecipitation with anti-PKCε antibodies (14). Immunoprecipitates 
obtained from cell lysates were separated by SDS-PAGE (8-10% polyacrylamide) and 
blotted to nitrocellulose membranes and probed with either anti-PKCε, anti-βactin or 
anti-pSer and anti-pThr antibodies (1).  
 
Mass Spectrometry 
PKCε monoclonal antibody was conjugated to protein-G (PG) agarose beads 
by incubating antibody with beads for 2 hours at room temperature. PG beads were 
washed with PBS, washed with borate buffer (0.2M Sodium Borate pH9.0), then 
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incubated with borate/DMP buffer (0.2M Sodium Borate pH9.0, 20mM dimethyl 
pimelimidate) for 1 hour at room temperature.  After incubation, the beads were 
incubated with 0.2M ethanolamine twice then incubated in 0.2M ethanolamine for 2 
hours room temperature. Beads were transferred to a column and washed with 1% OG 
lysis buffer (1% Octylglucoside, 50mM Tris-HCl pH 7.4, 150mM NaCl, 1mM CaCl2, 
2mM MgCl2, 1mM PMSF, 1mM benzamidine, 0.01 % aprotinin, 0.1% BSA). PKCε 
was immunoprecipitated on the column from lysates of MTF7L cells activated for 30 
minutes in 20%FBS/DME in suspension and immunoprecipitates resolved by SDS–
PAGE on 8% or 10% gels. Proteins were visualized with Colloidal Coomassie blue for 
MALDI TOF m/s, and protein bands were excised and sent for mass spectrometry 
analysis on MALDI-TOF/TOF 4700 Analyzer (Applied Biosystems) by The 
Proteomics and Mass Spectrometry Core Facility, Cornell University.  
 
Filamentous actin assay 
 An actin binding spin-down assay kit, for non-muscle actin (Cytoskeleton Inc, 
Denver, CO) was used to examine the interaction between PKCε and actin. Briefly, 
filamentous actin was allowed to form in compatible buffer from globular actin and 
purified PKCε was added to the solution to react for 30 min. The reaction mixture was 
ultracentrifuged and separated into supernatant (S) and pellet (P) fractions. S and P 
fractions were resolved by SDS-PAGE, stained with Coomassie blue and Western 
probed with anti- PKCε. 
 
Confocal microscopy 
Confocal microscopy was used to monitor cytoskeletal actin structure in 
MTF7L breast cancer cells. Tumor cells that had been subjected to EoE suspension 
culture were washed twice in DMEM containing 1% bovine serum albumin (BSA), 
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permeabilized with permeabilization buffer (0.5% TX-100, 20mM HEPES, 3mM 
MgCl2, 50mM NaCl, 300mM sucrose, 0.02% NaN3) at room temperature for 10 min, 
then incubated with phalloidin—fluorescein (to stain for filamentous actin) or mouse 
anti-PKCε diluted 1:50 or 1:300, respectively, in PBS containing 1%BSA (PBS-BSA) 
for 1h at 4°C . After washing in PBS-BSA, tumor cells stained with phalloidin were 
fixed in 2% paraformaldehyde in PBS and those stained with PKCε were washed 
twice with 0.1% Tween20 in PBS, stained with PE conjugated anti-mouse antiserum 
for 1h at 4°C, washed twice, then fixed. In select experiments, cells were stained with 
rabbit anti-Fn as described. Coverslips were mounted onto glass slides using Prolong 
Antifade (Molecular Probes, Eugene, OR) and viewed by laser scanning confocal 
microscopy (LSCM). An Olympus Fluoview 500 confocal laser scanning imaging 
system equipped with argon, krypton, and He-Ne lasers on an Olympus IX70 inverted 
microscope with a PLAPO 60× objective was used (Olympus America, Inc., Melville, 
NY). Confocal images were processed using Adobe Photoshop 6.0 (Adobe Systems, 
Inc., Mountain View, CA).  
 
RESULTS 
 
Mass spectrometry of PKCε complex in MTF7L reveals two cytoskeletal 
interacting proteins 
To identify potential interacting proteins within the PKCε signaling complex, 
we used a PKCε immunoaffinity column. Proteins that co-immunoprecipitated with 
PKCε were visualized with Coomassie staining (Fig 3.1A). The bands were excised 
from the SDS-PAGE gels and subjected to MALDI TOF m/s analysis. Analysis 
revealed two cytoskeletal proteins that were associated with PKCε, myosin IIa and β-
actin-2. In this paper, we shall examine the contribution of β-actin-2 to PKCε-  
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Figure 3.1:  PKCε associates with β-actin: (A) Coomassie blue staining and 
western blot of PKCε complex:  MTF7L cells were suspended in 20% FBS/DMEM 
for 30 minutes then lysed and immunoaffinity purified on an anti-PKCε antibody 
conjugated protein G column. Bound proteins were resolved by SDS-PAGE, the gel 
was stained with Colloidal Coomassie blue, and protein bands were excised for 
MALDI TOF m/s analysis. Corresponding fractions were ran in duplicate for Western 
blotting.  (B) β-actin co-immunoprecipitates with PKCε. Immunoaffinity-purified 
PKCε fractions #E3 and #E4 from lysed MTF7L cells treated as described above were 
Western probed with anti-β-actin antibodies. PKCε and β-actin co-immunoprecipitate, 
while corresponding control mIgG fraction is negative for both PKCε and β-actin. 
(C,D) PKCε binds F-actin. Immunoaffinity purified PKCε was subjected to an F-
actin binding assay using Biochem Actin binding spin-down assay kit as described in 
Material and Methods. Coomassie blue staining (CB) reveals F-actin co-sedimentation 
of positive control α-actinin, no co-sedimentation for negative control bovine serum 
albumin (BSA) (C) and PKCε co-sedimentation with F-actin in both eluted fractions 
E3 and E4 of purified PKCε (D), as confirmed by Western blotting (WB). S,  
supernatant. P, pellet.  
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mediated polyFn assembly. To confirm the results of MALDI TOF m/s analysis, we 
used anti-βactin antibody to specifically detect βactin in immunoprecipitates of 
PKCε. βactin co-immunoprecipitates (co-IP) with PKCε, but not with control 
mouse(m)IgG nonspecific immunoprecipitates (Fig 3.1B).  
To determine whether PKCε binds to functional actin filaments, an in vitro 
filamentous actin (F-actin) binding assay was performed. Results reveal that PKCε 
does indeed bind to F-actin, suggesting a cytoskeletal involvement in PKCε-mediated 
polyFn assembly (Fig 3.1C). 
 
PKCε and F-actin co-immunoprecipitate and colocalize at the subplasmalemmal 
space beneath polyFn aggregates 
PKC subcellular localization determines the specificity of kinase action on 
cellular function. Interactions with actin-binding proteins, RACKs or direct interaction 
with actin can position activated PKC at specific membrane domains in proximity of 
suitable substrate proteins, and further promote substrate phosphorylation. To 
determine whether PKCε and actin colocalizes at a certain cellular compartment, we 
utilized fluorescent confocal microscopy to examine the redistribution of activated 
PKCε in MTF7L cells following suspension culture in FBS. MTF7L cells were treated 
in EoE suspension in 20% FBS and endogenous PKCε was stained with red 
fluorescence while filamentous actin (F-actin) was stained with green fluorescence 
with phalloidin-fluorescein. Staining of PKCε and F-actin and their co-localization is 
monitored as a function of time in EoE suspension culture (Fig 3.2). At 5 min of EoE 
suspension culture, much of the PKCε and F-actin are dispersed in a punctate manner 
throughout the cytoplasm with some F-actin lining the subplasmalemmal space. There 
is no co-localization of the two molecules. At 10 min of incubation, PKCε and F-actin  
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Figure 3.2: PKCε colocalization with F-actin in activated MTF7L cells is time 
and cytoskeletal integrity-dependent: MTF7L cells subjected to EoE suspension for 
5, 10 or 30 minutes were stained with anti-PKCε or phalloidin-FITC (for F-actin) and 
analyzed by confocal microscopy. Confocal images of cells were merged and 
colocalized images isolated. MTF7L cells show increasing, time-dependent 
colocalization of PKCε-F-actin in the subplasmalemmal region.  
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have both co-segregated to the subplasmalemmal space, where they co-localize in a 
punctate manner reminiscent of the distribution of polyFn globules on the cancer cell 
surface. At 30 min of incubation, co-localization of PKCε and F-actin in the 
subplasmalemmal space is further pronounced. 
Confocal microscopy data were complemented by biochemical analyses. 
MTF7L cells subjected to EoE suspension culture for various periods of time were 
lysed, and lysates subjected to immunoprecipitation with anti-PKCε antibody. Western 
blotting of anti-PKCε immunoprecipitates shows that the association of PKCε and 
actin peaks at 15 minutes, then decreases drastically afterwards (Fig 3.3A). As we 
have shown previously (4), PKCε phosphorylation peaks at 15 minutes in suspension, 
correlating to the time point at which PKCε and actin binding occurs at maximum as 
detected by Western blotting. To determine whether PKCε activity is required for this 
PKCε-actin association, the inhibitor BIMXI was used at PKCε-inhibitory 
concentration. BIMXI caused a significant decrease in the association of PKCε and 
actin after drug inhibition (Fig 3.3B), indicating that PKCε activity is critical in 
mediating binding of PKCε to the actin cytoskeleton and activation of PKCε most 
possibly occurs before PKCε-actin association. 
 
F-Actin cytoskeletal integrity is necessary for polyFn assembly and proper PKCε 
localization  
The presence of an intact cytoskeleton has been shown to be critical for Fn 
matrix assembly in adherent cells (15). The ability of cytoskeleton to control 
fibronectin assembly may be mediated through regulation of the integrin functional 
state by interaction with cytoplasmic tails of β integrin (15) or to support proper PKC 
signaling complex localization (16). To examine whether cytoskeletal integrity is  
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Figure 3.3: PKCε and actin association: (A) PKCε-actin association is time-
dependent. MTF7L cells are treated with FBS for the time points 0, 15, and 30 
minutes and PKCε was immunoprecipitated and detected by Western blotting. Blots 
were subjected to staining with anti-β-actin antibody or anti-PKCε antibody. (B) PKCε 
-actin association is inhibited by BIMXI. MTF7L cells were trypsinized and treated 
BIMXI (500nM, PKCε inhibitor) for 15 minutes and suspended in 20% FBS/DMEM 
for 0, 15 and 30 minutes, and processed as above.  
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Figure 3.4: PolyFn assembly is dependent on cytoskeletal integrity: Actin 
depolymerizing drugs, Cytochalasin D (A) and Latrunculin B (B), block polyFn 
assembly. MTF7L rat breast cancer cells were exposed for 30min to 1uM, 10uM and 
20uM of Cytochalasin D or 200nM and 1uM of Lantrunculin B, and then subjected to 
EoE suspension culture for 1 hour in the presence of the drug. Cells were stained for 
poly-Fn and analyzed by FACS, showing a dose-dependent inhibition of polyFn 
assembly that is confirmed densitometrically and by immunocytochemistry. (C) Cells 
treated with solvent (DMSO) or Cytochalasin D (CytD), were EoE cultured for 30 
minutes in 20% FBS, and then immunostained and processed as described in Figure 
3.2. Data show co-localization of PKCε and F-actin in the subplasmalemmal space of 
DMSO-treated cancer cells and cytoplasmic clusters of PKCε/F-actin complexes in 
Cytochalasin D-treated cells. 
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critical for polyFn assembly of breast cancer cells during suspension, we used two 
inhibitors known to disrupt actin polymerization, Cytochalasin D and Latrunculin B. 
Both inhibitors were able to block polyFn assembly in MTF7L cells in dose-dependent 
manners (Fig 3.4A&B), with Cytochalasin D having a more prominent effect.  
Cytochalasin D impedes actin polymerization by binding to barb ends of actin 
filaments, blocking addition of monomeric actin to actin filaments, while Latrunculin 
B blocks actin polymerization by binding to monomeric actin (17,18). The distinct 
mechanisms of the two inhibitors may explain the differences in the inhibitory activity 
on polyFn assembly. 
To determine whether disturbance of actin cytoskeletal organization would 
perturb the subcellular localization of the PKCε-actin complex, we used the stronger 
inhibitor of polyFn assembly, Cytochalasin D. Cytochalasin D treatment resulted in 
increased cytoplasmic localization of the PKCε-actin binding complex (Fig 3.4C), 
which is paralleled by diminished polyFn. By altering the subcellular localization of 
PKCε-actin, Cytochalasin may render PKCε unable to activate downstream signaling 
components leading to inhibited polyFn assembly. These results suggest that an intact 
cytoskeletal structure is necessary for and supports the proper localization of the PKCε 
complex to transduce signals leading to polyFn assembly. 
 
Deletion of proposed Protein kinase Cε actin-binding site is insufficient to block 
polyFn assembly  
A unique actin binding domain of PKCε that is homologous to other actin 
binding proteins has been identified and localized to amino acids 223-228, located 
between the C1A and C1B domains (19). A mutant protein lacking this actin binding 
site is able to perturb proper neurite formation but does not alter its subcellular  
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Figure 3.5: PKCε actin binding motif is not essential for polyFn assembly: 
MTF7L breast cancer cells were transfected with wild type PKCε or PKCε deleted of 
its actin binding domain (cloned into pEGFR-N1), immunostained and analyzed for 
poly-Fn on FACS. X-axis gates were selected based on the staining of MTF7L cells 
with non-immune rabbit IgG. Y-axis gates were selected based on 50% Fn staining 
intensity of the vector transfected GFP-positive cells. Cells in the upper right quadrant 
of the scatter gram (strong expressers of PKCε and Fn) were expressed as percent of 
the sum of cells in the right upper and lower quadrants (strong PKCε expressers), 
providing a quantitative measure of the inhibitory activity of PKCε−△ABD (A). Cell 
lysates from transfected cells were blotted with anti-GFP antibody to show equal 
expression levels (B) and also immunoprecipitated with anti-GFP and blotted with 
actin to show the actin binding activity of each construct (C). (D) Adenovirus-
mediated expression of PKCε−△ABD shows identical results. AdWTε, adenoviral 
PKCε−WT. AdABDε, adenoviral PKCε−△ABD. 
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localization in cells compared to the wild type protein (20). We generated a PKCε 
construct lacking amino acids 223-228 (PKCε− △ ABD) in order to investigate 
whether deletion of this domain will negatively affect PKCε mediated polyFn 
assembly. Surprisingly, transfection of PKCε−△ABD into MTF7L cells failed to 
block surface expression of polyFn (Fig 3.5A). This was not due to differential 
expression of the transfected proteins, as shown by equal GFP-tagged protein 
expression (Fig 3.5B). Overexpression of PKCε−△ABD from adenoviral vectors with 
over 90% transduction rate in MTF7Ls also failed to have any effect on polyFn (Fig 
3.5D). These data suggest that the proposed actin binding domain does not have a 
direct role for PKCε regulated polyFn assembly in MTF7L cells. We then examined 
whether the mutant PKCε, PKCε− △ ABD, is still able to bind β-actin. 
Immunoprecipitation of the transfected protein PKCε− △ ABD revealed that this 
mutant PKCε still binds β-actin, but seems to have weaker affinity compared to wild 
type PKCε (Fig 3.5C). It is possible that this residual actin binding still plays a role in 
supporting polyFn assembly, and that under these circumstances, an alternative 
pathway or accessory proteins exists in MTF7L cells that is able to compensate for the 
loss of the actin binding domain in PKCε. The fact that PKCε−△ABD was previously 
found to localize to the same compartments as wild type PKCε (20) also further 
highlights the importance of proper PKCε localization to the cortical cytoskeleton. 
 
Pyk2 kinase activity is required for polyFn assembly 
 Pyk2 has been known to have a role in actin cytoskeleton organization in 
processes such as cell adhesion and cell migration of several cell types (21). The 
autophosphorylation and activation of Pyk2 is stress fiber-dependent (21) and its 
activation is PKCε-dependent in myocytes (7). These facts prompted us to investigate 
whether or not Pyk2 kinase activity plays a role in polyFn assembly. A Pyk2 kinase 
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dead (K475A) mutant (Pyk2-KD) was used to transfect MTF7L cells in comparison to 
Pyk2 wild type (Pyk2-WT). Wild type and kinase dead mutant of the other focal 
adhesion kinase member, FAK, were also transfected in MTF7 cells for comparison. 
24 hours after transfection, the cells were subjected to EoE suspension culture for 1h, 
then stained with anti-Fn antibody to detect surface assembled polyFn. Results show 
that the introduction of kinase dead Pyk2 partially impaired the ability of the cells to 
form surface Fn aggregates (Fig 3.6A&B), demonstrating the active role of Pyk2 
during the course of polyFn formation on the cancer cell surface. In contrast, kinase-
dead FAK had no effect on polyFn assembly (Fig 3.6A).  
To further examine whether or not Pyk2 autophosphorylation correlates with 
the course of polyFn assembly in our assay, MTF7L cells were serum-starved 
overnight and incubated in an EoE suspension culture in FBS for the indicated time 
points. Cell lysates were probed for phosphorylated Pyk2 content (pPyk2). The time 
course experiment indicated that pPyk2 peaked at 10 minutes of incubation (Fig 3.6C), 
coinciding with the peak of PKCε phosphorylation as previously shown (4). The close 
occurrence of phosphorylation of PYK2 and PKCε suggests that one protein could be 
regulating the phosphorylation of the other. Since a previous study in rat ventricular 
myocytes has shown that PKCε regulates Pyk2, we were eager to know whether or not 
diminished PKCε will have an effect on Pyk2 activation. Indeed, the PKCε inhibitor 
BIMXI concentration markedly decreased phosphorylation of Pyk2 (Fig 3.6D). 
Similar results were obtained when cells were treated with Cytochalasin D (Fig 3.6D). 
This suggests that Pyk2 activation is downstream of PKCε and that abnormal 
subcellular localization of PKCε under disrupted cytoskeletal organization will 
abrogate PKCε downstream signaling to Pyk2. 
 Salicylate, the known Pyk2 inhibitor, is able to abrogate the phosphorylation of 
the PKCε mediated Pyk2 phosphorylation (22). We tested this inhibitor for its effects  
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Figure 3.6: Pyk2 kinase activity is required for polyFn assembly: (A&B) MTF7L 
breast cancer cells were transiently transfected with wild type or kinase-dead FAK and 
Pyk2 and 24h later subjected to EoE suspension culture in DMEM+20%FBS for 1h at 
37℃. Cells expressing equal amounts of wild type and kinase-dead FAK and Pyk2 
were stained with anti-Fn antibodies and analyzed by dual-color FACS as described. 
(A) and Fn-immunocytochemistry (B). Kinase-dead Pyk2 but not FAK impairs polyFn 
assembly. (C) Time-dependent Pyk2 phosphorylation: Pyk2-transfected MTF7L cells 
were suspended for the indicated time periods in DMEM+20%FBS, then lysed. 
Lysates were separated by SDS-PAGE, blotted onto nitrocellulose and probed with 
phosphor-specific Pyk2(Y402) antibody or anti-Pyk2 antibody. (D) BIMXI and 
Cytochalasin D (CytD) inhibit Pyk2 phosphorylation: MTF7 cells were trypsinized 
and treated with BIMXI (500nM) or CytD(1μM) for 15 min, then subjected to EoE 
suspension in 20% FBS/DMEM for 0,15, and 30 min, lysed and lysates resolved by 
SDS-PAGE (10% gel) and Western probed with anti-Pyk2 and phosphor-specific anti-
Pyk2 antibodies. (E) MTF7L cells pretreated with sodium salicylate (10 or 20mM) for 
30 min, then subjected to EoE suspension (1h; DMEM+20%FBS) were stained with 
anti-Fn and analyzed by FACS. The Pyk2 inhibitor salicylate inhibits polyFn assembly 
in a dose-dependent manner. 
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on polyFn and found that it abolished polyFn formation at the proposed working 
concentrations (Fig 3.6E).  
 
DISCUSSION 
 
Early work on PKCε has linked it to oncogenic transformation of cells. The 
oncogenic activity has been reported in fibroblasts, colonic cell lines, prostate 
epithelial cell lines and breast cancer cell lines (23-26). In mice, epidermis-specific 
transgenic overexpression of wild type PKCε resulted in development of metastatic 
squamous cell carcinomas (27). High-density tissue microarray analysis revealed 
significant positive correlation between PKCε and tumor histologic grade, while 
knockdown of PKCε reduced breast cancer cell invasiveness and lung metastasis (26). 
In our previous study, impairment of PKCε in rat breast cancer cells by a dominant 
negative construct and specific drug inhibitors leads to decreased polyFn assembly and 
reduced lung colonization (4). The converging signaling events of PKCε and the actin 
cytoskeleton is a potential mechanism underlying these oncogenic processes.  
Many approaches have been used to identify PKC binding partners in order to 
understand the role of PKC in different cellular functions (28). Mass spectrometry 
results have showed that PKCε associates with proteins including β’Cop, cytokeratins, 
cardiac myofibrils, matrin3, transferin, Rac GAP1 and vimentin. (16,29,30). Many of 
the binding proteins identified within the PKCε complex are putative PKC substrates 
such as MARCKS and STICKS, while others are not phosphorylated by PKC and may 
function as anchoring proteins or regulators of substrate phosphorylation, facilitating 
integration of PKC signaling into other pathways (5,16,19,29). Our current study 
presents two cytoskeletal interacting partners of PKCε potentially involved in 
mediating polyFn assembly. This finding is consistent with a previous study 
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performed in fibroblasts (28), which found that both actin and myosin IIa co-
immunoprecipitated with PKCε but are not substrates of PKCε. We have tested the 
myosin ATPase inhibitors 2,3-Butadione monoxime (31) and blebbistatin (32) and it 
seems that myosin ATPase activity is not involved in our cellular function in polyFn 
assembly (Fig 3.7 A&B). Although PKCε does not directly regulate myosin 
phosphorylation (28), it is still possible that PKCε is able to modulate myosin activity 
non-catalytically or that myosin can regulate PKCε activity. The role of myosin IIa in 
the PKCε complex may also be to bridge PKCε to actin stress fibers or to strengthen 
the association of PKCε and F-actin. 
PKC activity is regulated through differential recruitment by PKC isotype-
specific binding proteins localized in different subcellular domains, which facilitates 
PKC localization to activate proteins in a particular cellular compartment (19,30,33). 
Subcellular localization is a key event in PKC functional and regulatory specificity. 
We show that both PKCε activity and cytoskeletal integrity is required for PKCε-actin 
association in MTF7L cells and that PKCε increasingly associates with actin in a time 
dependent manner. Inhibition of PKCε activity diminishes this response, suggesting 
that the catalytic component of PKCε could play a role in either its initial binding to 
actin or strengthen the binding interaction and that PKCε must be activated before 
binding to the actin cytoskeleton. Perturbing the cytoskeleton by Cytochalasin D 
prevents PKCε translocation from the cytoplasm to the plasma membrane, resulting in 
abrogation of polyFn assembly on tumor cell surfaces. Therefore, we propose that 
upon PKCε activation, PKCε binds to intact F-actin cytoskeleton, which sustains 
PKCε activity and PKCε translocation to the plasma membrane and facilitates 
downstream activation of Pyk2 to promote successful polyFn assembly. 
Interaction between PKCε and F-actin has been shown to activate PKCε 
(19,34) and the PKCε actin binding domain has been mapped to amino acids 223-228.  
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Figure 3.7: Inhibitors of myosin ATPase activity had no effect on polyFn 
assembly: MTF7L cells pretreated with blebbistatin (100μM or 200μM) (A) and 2,3-
Butadione monoxime (BDM) (20 μM) (B) for 30 min, then subjected to EoE 
suspension (1h; DMEM+20%FBS) were stained with anti-Fn and analyzed by FACS.  
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In our results, deletion of the proposed actin binding site of PKCε was insufficient to 
block the formation of polyFn on breast cancer cells and PKCε activation seems to be 
a prerequisite for actin binding. Immunoprecipitation of wtPKCε-GFP and PKCε−△
ABD -GFP revealed residual levels of actin binding. The residual actin binding may 
be due to the existence of an alternate actin binding site of PKCε or through 
alternative pathways via supporting proteins such as other actin-binding proteins 
within the cells that can bind PKCε to the cytoskeleton. On the other hand, the fact 
that PKCε−△ABD overexpression failed to abrogate polyFn assembly could be due to 
the fact that PKCε−△ABD still retains the wild type protein subcellular localization 
(20) and that subcellular localization is the crucial factor in the relationship of actin 
cytoskeleton and PKCε in this study. The proximity of both wild type PKCε and 
PKCε−△ABD, which both possess the catalytic domain, to the cytoskeleton and/or 
plasma membrane compartment may be the main feature responsible for downstream 
signaling leading up to polyFn assembly. Hence, the mere absence of the actin-binding 
site may not be truly sufficient to induce a significant effect on polyFn formation 
when the mutant protein maintains proper localization that supports PKCε to activate 
the necessary proteins at its cytoskeletal signaling site. 
 Pyk2 and FAK are highly homologous in sequence and share a similar 
structural organization (35). Despite of the high similarity, the two proteins seems to 
be differentially regulated. Although phosphorylation of FAK and Pyk2 can both be 
controlled by integrin engagement, Pyk2 response to soluble factors such as 
angiotensin II is dramatically stronger in certain cells, while FAK is mainly regulated 
by integrin-mediated cell adhesion (35). Pyk2 and FAK also associate with the 
cytoskeleton and with integrin signaling complexes by complexing to proteins such as 
Src kinases, p130 Cas, paxillin and Graf1 (36). FAK C-terminal domain binds the 
integrin-associated protein talin while Pyk2 binds the actin-associated protein gelsolin 
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(37), which can further account for their differential functions. In this study, we show 
that Pyk2 is the main adhesion kinase responsible for downstream signaling from 
PKCε to polyFn assembly of MTF7L cells, indicated by the ability of kinase dead 
Pyk2 and the Pyk2 inhibitor salicylate to impair polyFn formation. Inhibition of PKCε 
by BIMXI, which also blocks polyFn assembly (4), inhibits time-dependent activation 
of Pyk2 in MTF7L cells. The relationship of PKCε and Pyk2 is consistent with a 
previous study which shows that constitutively active PKCε increases endothelin-1 
induced Pyk2 phosphorylation while kinase inactive PKCε inhibited Pyk2 
phosphorylation (7). Pyk2 has been implicated in integrin inside-out signaling by 
associating with beta3 integrins (38) and this could be a possible pathway by which 
Pyk2 regulates polyFn assembly. The phosphorylated beta3 integrin cytoplasmic tail 
provides a binding site for Pyk2 (8). Pyk2 has the FERM domain that contains a 
phosphotyrosine binding domain (PTB) domain similar to talin, which is also able to 
bind beta3 tail and trigger activation for ligand binding (39). Cellular signal induces 
the conformational change of talin allowing it to bind to the beta integrin tail and 
unclasps the complex between the alpha and beta integrin cytoplasmic tails, which 
causes a conformational shift in the extracellular head domain and renders it more 
extended for high affinity ligand binding (39). Pyk2 binding to the integrin 
cytoplasmic tails could have a similar impact on the polyFn receptor and activate the 
integrins for fibronectin binding and subsequent polyFn assembly.  
Results obtained in this study are summarized in Fig 3.8A. In our working 
model (Fig 3.8B), we propose that in MTF7L cells subjected to EoE suspension 
culture PKCε is activated and phosphorylated and associates with F-actin in the 
cytoplasm, presumably at secretory vesicle located in the vicinity of the Golgi 
complex (Fig 3.2, arrows). The PKCε-actin complex then translocates in increasing  
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Figure 3.8: Diagram of cellular processes in polyFn assembly: (A) Summary of 
effects of various treatments performed in this study, providing the relationship of 
subcellular localization of PKCε, actin and polyFn. (B) Signaling pathway in polyFn 
assembly. Soluble ligands in the plasma activates PKCε through receptor binding, 
PKCε translocates to the membrane and cortical cytoskeleton, activates PYK2 in 
proximity. Activated PYK2 activates the beta integrin cytoplasmic tail domain and 
extracellular domain of integrin is rendered extended for ligand binding. 
Phosphorylated protein marked with “p”. 
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amounts (10-30min) to the subplasmalemmal space, which is prevented by 
Cytochalasin D as shown by the intracellular accumulation of PKCε/actin complexes 
(Fig 3.4). Whether the PKCε-mediated activation of Pyk2 happens immediately 
following complexing of PKCε/F-actin in the cytosolic compartment or at the plasma 
membrane in unclear. However, strong phosphorylation of Pyk2 as early as 1-5 min 
after subjecting MTF7L cells to EoE suspension culture (Fig 3.6C), i.e., prior to the 
appearance of PKCε/F-actin complexes in the subplasmalemmal space (Fig 3.2), 
suggests that Pyk2 is activated in the cytosol. At Golgi-derived secretory vesicles (Fig 
3.2, arrows), PKCε and/or Pyk2 could well serve as activator(s) of β integrins, 
collaborating with talin to promote integrin activation and clustering (39) and to 
initiate the assembly of Fn/integrin complexes in secretory vesicles. As secretory 
vesicles fuse with plasma membrane, Fn is exposed at the cell surface, where it serves 
as a scaffold for Fn-Fn self association with plasma Fn into insoluble polymeric 
complexes (1). Such mechanism is supported by siRNA Fn-knockdown experiments 
in which polyFn is dramatically reduced, albeit cancer cells are exposed to high 
plasma Fn concentration in EoE suspension culture (4). Similarly, human MCF7 
breast cancer cells that do not express Fn yet have a similar β1 integrin expression 
profile as MTF7L (40) are unable to assemble polyFn on their surfaces in medium 
containing 20% FBS or plasma Fn (Pauli et al., personal communication). Together, 
our data provided novel information of the polyFn assembly process, that in previous 
studies from our laboratory has been shown to be an integral part of cancer cells’ 
ability to colonize the lungs (1,2,4). 
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 PKC EPSILON-MEDIATED REGULATION OF POLYMERIC 
FIBRONECTIN ASSEMBLY  
 
 Overexpression of fibronectin (Fn) has been demonstrated in 
invasive/metastatic breast tumors and tumor cells from primary invasive ductal breast 
carcinomas (1-3) as well as cell lines such as MDA-MB-231 and MTF7, and is 
especially prominent in cell lines selected for enhanced lung metastatic ability (4,5). 
Survey of all our highly lung-metastatic breast cancer cell lines revealed high levels of 
Fn expression (4). Tumor cells that were isolated from the blood of tumor-bearing 
animals are characterized by a cell surface coat of multi-globular polyFn, which could 
be reproduced on the cell surface of cancer cells subjected to suspension culture in the 
presence of serum. This surface coat of polyFn mediates the docking of breast cancer 
cells MTF7 to the lung endothelial addressin DPP IV and facilitates lung colonization 
(4,6-8). In this study, the mechanism of polymeric fibronectin formation on the surface 
of breast cancer cells was investigated. We found that protein synthesis and secretion 
is crucial for the polyFn assembly process and knockdown of endogenous cellular 
fibronectin impedes both the formation of surface polyFn and pulmonary metastasis of 
the cancer cells. PolyFn assembly is regulated by PKCε. Pharmocological inhibition of 
PKC, transfection of dominant negative regulatory domain mutant of PKCε and 
knockdown of PKCε protein all decreased surface polyFn in MTF7 cells. PKCε 
translocates to the membrane in increasing amounts during the course of polyFn 
assembly, which is accompanied by phosphorylation of PKCε on serine and threonine 
residues. In contrast, transfection of dominant negative PKCδ and knockdown of 
PKCδ promoted polyFn assembly, in accordance with the proposed opposing effects 
of PKCε and PKCδ (9). 
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  In order to further understand how PKCε reglates polyFn assembly, we utilized 
mass spectrometry to identify possible regulating factors residing within the PKCε 
complex formed during suspension incubation. Two cytoskeletal proteins were found 
within the PKCε complex, β-actin and myosin IIa. Myosin ATPase activity is not 
required for polyFn assembly, as evidenced by lack of effect of pharmacological 
inhibitors. On the other hand, β-actin associated with PKCε in a time-dependent and 
PKC activity-dependent manner, and filamentous actin associated with PKCε 
increasingly at the subplasmalemmal space. The actin depolymerizing drug, 
Cytochalasin D, disrupted formation of polyFn and perturbed the subplasmalemmal 
localization of the PKCε-actin complex. The images of PKCε-actin complexes within 
the cells showed a few cytoplasmic granule-like existence while images from 
Cytochalasin D treated cells demonstrated a tremendous amount of cytoplasmic 
complexes. Since PKCε has been implicated in various exocytic processes (10-12), 
these observations raise the question of whether the PKCε-actin complexing could be 
involved in exocytosis of fibronectin or polyFn receptors. 
 One of the focal adhesion kinase family members, Pyk2, was also shown to be 
involved in polyFn assembly. Transfection of a kinase dead mutant of Pyk2 and 
pharmacological inhibition with the Pyk2 inhibitor sodium salicylate both decreased 
surface polyFn assembly, and time-dependent phosphorylation of Pyk2 was blocked 
by the PKCε inhibitor BIMXI and Cytochalasin D, suggesting that Pyk2 
phosphorylation was downstream of cytoskeletal integrity and PKCε activity. Pyk2 
possess the same FERM domain by which talin, a cytoplasmic cytoskeletal protein 
that regulates integrin ligand binding affinity via inside-out signaling (13), binds 
integrin cytoplasmic tails. Pyk2 has also been shown to bind to β3 integrin 
cytoplasmic tails (14). Therefore, we propose in our working model that PKCε 
regulates polyFn assembly by signaling downstream to Pyk2 and allowing Pyk2 to 
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 relay the signal to β3 integrin cytoplasmic tails, in turn altering integrin ligand binding 
affinity to bind fibronectin, allowing cells to form a fibronectin scaffold that facilitates 
fibronectin self-association and build up of polymeric fibronectin globules on the 
surface of cancer cells. 
 The soluble factor responsible for triggering the polyFn assembly cascade has 
not been identified. This factor could be a cytokine secreted by the cancer cells and 
could act in an autocrine manner. The factors tested in this study are listed in Table 1. 
Negative results may indicate either: the factor was not involved, the factor was 
insufficient to trigger an active response, the concentration used was not optimal, or 
the activating conditions were not optimal. The conditioned medium isolated from 
MTF7 culture was able to induce an increase in polyFn assembly (Fig 4.1A). Two 
soluble factors were identified in the conditioned medium of MTF7 cells, monocyte 
chemotactic protein-1 (MCP-1) and tissue inhibitor of metalloproteinase (TIMP-1) 
(Fig 4.1B), and MCP-1 was tested and shown to be unable to increase polyFn 
compared to control (Table 1). Future analysis of the conditioned medium of MTF7 
cells with cytokine arrays that test for a greater number of cytokines than the 18-
cytokine array used may be helpful in identifying the “trigger” factor. 
Future investigations on the receptor(s) of polyFn may present evidence to 
support the detailed mechanism in PKCε regulation of poly Fn assembly. The first 
candidate to test would be β3 integrin, binding target of Pyk2. To test the hypothesis 
that β3 integrin is the polyFn receptor subunit, the first step is to confirm the 
expression of β3 integrin in MTF7 cells. Subsequently, imaging studies can be done to 
visualize the colocalization of β3 integrin and polyFn globules. A possible interaction 
may be further characterized by attempting to co-immunoprecipitate β3 integrin and 
polyFn in biochemical analysis. To further investigate the requirement for inside-out 
signaling in β3 integrin activation, mutants of β3 integrin cytoplamic tail, which has  
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Table 1: Stimulators tested for polyFn assembly. 
 
Reagents tested negative as stimulator of polyFn assembly* 
Drug/reagent Concentration used 
Lysophosphatidic acid (LPA) 5μM, 10 μM, 20 μM, 
Phosphatidylinositol(3,4) bisphosphate (diC8) 10μg/ml 
Inositol hexakisphosphate (InsP6) 200μM 
m-3M3FBS, phospholipase C activator 25 μM, 50 μM 
Epidermal growth factor (EGF) 100ng/ml 
Insulin-like growth factor (IGF-1) 100ng/ml, 200ng/ml, 500ng/ml 
Stromal cell-derived factor alpha (SDF-1) 300ng/ml, 600ng/ml 
 
Platelet derived growth factor (PDGF) 20gn/ml, 100ng/ml 
Transforming growth factor beta (TGFβ) 10pg/ml, 20pg/ml, 50pg/ml, 500pg/ml 
Interleukin-8 (IL-8) 25ng/ml, 50ng/ml 
Thrombin 5units, 10units 
Sphingosine-1-phosphate (S1P) 500nM, 2.6μM 
Platelet-derived growth factor (PDGF) 50ng/ml, 100ng/ml, 500ng/ml, 1μg/ml 
Monocyte chemoattractant protein-1 (MCP-1) 100 ng/ml 
*comparison between MTF7 cells from 1 hour suspension in the presence of no 
drug, drug + no Fn, drug + Fn (20 μg/ml) in DMEM 
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Figure 4.1: Cancer cell secreted factors in polyFn assembly. (A) MTF7 cell 
overnight conditioned medium (CDME) was used to treat cells in EoE suspension 
culture, in comparison to medium (DME). Cells were stained with anti-Fn and 
analyzed with FACS. Results show cells treated with conditioned medium had an 
increased ability to assemble surface polyFn. (B) Rat cytokine array (Raybiotech, 
Norcross GA) of  MTF7 CDME shows secretion of monocyte chemotactic protein-
1 (MCP-1) and tissue inhibitor of metalloproteinase (TIMP-1). 
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 been shown to be crucial in integrin inside-out signaling (15), can be used in 
transfection experiments. Lastly, effects of knockdown of β3 integrin protein can also 
be determined. Clarification of the α integrin subunit partner of the possible polyFn β3 
integrin receptor could further be investigated by subcellular imaging, biochemistry 
and mutants. Fibronectin binding sites of β3 integrin could also be blocked using 
peptides or blocking antibodies. 
The involvement of the small GTPases such as Rho, Rac and Cdc42 would 
also be of interest due to their roles in cytoskeletal organization (16). To test the 
involvement of the small GTPases Rac and Cdc42 in polyFn assembly, dominant 
negative or constitutive mutants of Rac and Cdc42 can be transfected into MTF7 cells. 
Rac or Cdc42 activity can further be characterized by activity assays testing for GTP-
form binding to glutathione S transferase–p21-activated kinase (GST-PAK). 
Functional correlating effects of mutants on polyFn assembly in conjunction with 
activated Rac or Cdc42 in polyFn assembly phase would indicate a role for a Rho 
GTPase in surface polyFn formation. Moreover, the possible involvement of a 
cytokine such as CXCL1(Groα;Cinc1), which is downregulated 8-fold in PKCε-
depleted MTF7 cells relative to control cells, must also be considered. In support of 
this notion, CXCL1 binding to its receptor CXCR2 could have been responsible for 
the binding of RACK1 with Gβγ subunit of heterotrimeric G proteins and the observed 
translocation of activated PKCε to the plasma membrane (17). 
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APPENDIX 
 
CONDITIONAL KNOCKOUT OF FIBRONECTIN IN MAMMARY 
EPITHELIUM LEADS TO SEVERE LOBULO-ALVEOLAR HYPOPLASIA IN 
THE MOUSE MAMMARY GLAND* 
 
 
 
 
 
 
 
 
 
*  Liu K, Cheng L, Flesken-Nikitin A, Huang L, Nikitin AY and Pauli BU. 
Conditional Knockout of Fibronectin in Mammary Epithelium Leads to Severe 
Lobulo-Alveolar Hypoplasia in the Mouse Mammary Gland. To be submitted. 
(Huang L: Biochemistry, mice mating, genotyping, mammary gland extraction) 
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ABSTRACT 
 
Fibronectin (Fn) plays an important part in the branching morphogenesis of 
salivary gland, lung, and kidney. Here, we examine the effect of the conditional 
knockout of Fn in the mammary epithelium [FnMEp–/–] on postnatal mammary gland 
development, using Cre-loxP mediated gene knockout technology. Our data show that 
FnMEp–/– mice exhibit (i) a moderate retardation in outgrowth and branching of the 
ductal tree as well as a reduced number of terminal end buds (TEBs) in adolescent 
mice (5 weeks old) that became statistically indifferent to control mice [FnMEp+/–; 
Fnfl+/+] in virgin adult mice (16 weeks old), and (ii) severe lobulo-alveolar hypoplasia / 
aplasia in 15-day pregnant FnMEp–/– mice, resulting in inability to lactate and nurse. 
Both heterozygous FnMEp+/– and Fnfl+/+ control mice exhibit normal MG development 
and Fn expression. Lack of lobulo-alveolar differentiation during pregnancy of FnMEp–
/– mice is associated with significantly decreased rates of MEp proliferation, decreased 
numbers of MEps that had undergone ‘epithelial mesenchymal transition’ and invaded 
the surrounding fat pad, and decreased neovascularization, which was paralleled by a 
dramatic decrease in Vegf expression. Concomitant downregulation of β1 integrin 
(Itgb1) and decrease autophosphorylation of FAK suggest that this pathology is 
mediated, at least in part, by disruption of Fn/Intgb1/FAK signaling pathway. This 
notion is supported by the fact that conditional knockouts of Itgb1 and FAK generate 
the same pathology as Fn-deletion.  
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INTRODUCTION 
 
 Fibronectin (Fn) is an adhesive glycoprotein that is present in extracellular 
matrices (insoluble form) and in body fluids (soluble form; e.g., blood plasma). It 
exists as a dimer composed of nearly identical ~250 kDa subunits linked covalently 
near their C-termini by a pair of disulfide bonds. Each monomer consists of 3 types of 
repeats: 12 type I, 2 types II, and 15 type III (1-3). Although Fn molecules are the 
product of a single gene, the resulting protein can exist in multiple forms arising from 
alternative splicing of a single pre-mRNA (~20 variants in humans). Splice sites are 
EDA (Extra Domain A), EDB (Extra Domain B), and IIICS (type III connecting 
segment; also called variable [V] region) (4). This multi-domain structure harboring 
binding sites for cell adhesion receptors (e.g., integrins, syndecans, CD44, CD26), 
matrix macromolecules (e.g., collagens, hyaluronic acid, proteoglycans, tenascin, 
thrombospondin, fibrinogen), secreted, biologically important molecules (e.g., factor 
XIIIa, tissue transglutaminase, fibrinogen, heparin), as well as for Fn-Fn self-
association (5-8) makes it a perfect candidate for a ‘multi-task’ role. As such, it 
anchors the extracellular matrix to the cell cytoskeleton via adhesion receptors and, in 
doing so, relays signals from the milieu outside the cell to its inside. This so-called 
outside-in signaling accounts for the many functions with which Fn has been 
associated including cell adhesion, differentiation, growth, and migration (6,9,10). 
Thus, Fn is critical in vertebrate development, tissue morphogenesis and homeostasis, 
wound healing, angiogenesis, and cancer (1-4,9-13). Fn knockout is embryologically 
lethal, with abnormalities becoming manifest first at the onset of gastrulation (for 
details see 14,15). 
 Many organs, including glands, lung and kidney are formed during embryonic 
development by epithelial branching through a process of repetitive epithelial cleft and 
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bud formations. In an elegant organ culture study, Yamada and associates (16) showed 
that Fn is essential for cleft formation during the initiation of epithelial branching in 
the submaxillary gland. Fn messenger RNA and fibrils were expressed transiently and 
focally in forming epithelial cleft regions. Knockdown of Fn by small interfering RNA 
and by inhibition with anti-Fn or anti-integrin antibodies (anti-α5, -α6, and -β1) 
blocked cleft formation and branching, while exogenous Fn accelerated cleft 
formation and branching. Mechanistically, the authors implied that fibrillar Fn 
mediates cleft formation in branching morphogenesis by downregulating cadherins at 
cell-cell junctions, thereby converting cell-cell to cell-matrix adhesions. Although a 
similar scenario has not been established for the mammary gland (MG), the functional 
role of ECM proteins, including Fn, collagen type I, and laminin, in MG postnatal 
development has been studied more recently (17). Among the three ECM proteins 
only the Fn levels changed appreciably, increasing threefold between puberty and 
sexual maturity and remaining high during pregnancy and lactation. This temporal 
expression of Fn coincides with the expressions of hepatocyte growth factor (HGF; 
produced by mammary fibroblasts) (17-19), estrogen and progesterone (both shown to 
regulate Fn expression) (20). HGF levels rise at midpuberty and are maximal at sexual 
maturity and remain high during pregnancy, while estrogen is driving ductal 
development during puberty, and estrogen and progesterone mediate proliferation, 
ductal branching and alveologenesis at sexual maturity and during pregnancy (21,22). 
Moreover, blockade of AP-1 transcription factors, which inhibits expression of AP-1-
dependent genes (e.g., Fn, cyclin D, c-myc, TIMP-1, vimentin) suppresses branching 
and budding and reduces gland tree size and fat pad occupancy in developing MGs 
(23). More details of the genes involved in postnatal MG development have been 
provided by several, excellent review articles by Hennighausen and associates (24-26). 
Together these studies suggest that the temporal expression patterns of growth 
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regulatory molecules (e.g., cyclin D, c-myc, HGF, EGF), matrix macromolecules (e.g., 
Fn) and steroid hormones modulate mammary epithelial proliferation and 
morphogenesis by interacting Fn/integrin-, growth factor-, and steroid hormone-
signaling pathways, which ultimately may also harbor new clues of the role of these 
factors, particularly Fn, in mammary cancer progression (27). 
In this report, we present data of the role of Fn in the postnatal development of 
the mammary gland, using mice with MMTV-Cre-loxP conditional knockout of Fn in 
the mammary epithelium (FnMEp–/–). Our whole-mount, histologic, 
immunohistochemical, morphometric, biochemical, and functional data show that 
these mice exhibit (i) moderate retardation in outgrowth and branching of the ductal 
tree in virgin mice, and (ii) lack of alveolar budding and lobule formation during 
pregnancy and lactation, resulting in inability to lactate and nurse. Both heterozygous 
FnMEp+/– and Fn-floxed (Fnfl+/+) control mice exhibited near normal and normal MG 
development and Fn expression, respectively. Decreased mammary epithelial cell 
(MEp) proliferative rates in FnMEp–/– mice and altered signaling via the β1 integrin 
(Itgb1) Fn receptor and focal adhesion kinase may have accounted, at least in part, for 
the observed result. 
 
MATERIAL AND METHODS 
 
Conditional Knockout of Fn in Mouse Mammary Epithelium 
 Heterozygous, male Fnfl+/– carrying loxP sites within the 5’ untranslated region 
at the Msc1 site and within the first intron at the Nhe1 site of the Fn gene were 
generated in Dr. Fässler laboratory (Max-Planck-Institute, Martinsried, Germany) 
(28). These mice were backcrossed with wild type FVB mice to produce heterozygous 
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Fnfl+/– mice. The heterozygous Fnfl+/– mice were crossed with siblings to generated 
homozygous Fnfl+/+ mice. To introduce Cre-recombinase [an enzyme that cleaves loxP 
sites, thereby removing the start codon, signal sequence and the exon/intron border of 
exon 1 of Fn to generate the Fn-null allele 28)] that is under control of the mammary 
epithelial cell-specific MMTV LTR promoter into Fnfl+/+ mice, Fnfl+/+ females were 
paired with male MMTV-Cre mice with an FVB genetic background (supplied by Dr. 
Guan, University of Michigan) to ultimately obtain female mice with the genotype 
MMTV-Cre+ Fnfl+/+ and the phenotype FnMEp–/–. Offspring with the desired genotypes 
were identified by PCR analysis of tail DNA, using the same primer sets as described 
by Fässler and associates (28). Control mice were heterozygous FnMEp+/– and Fnfl+/+ 
mice. Mice were analyzed at 5- and 16-weeks of age and at day 15 of pregnancy (13 to 
14 weeks of age). 
 To assure selectivity of Cre-recombinase activity in MEp, we stained frozen 
sections (5 µm thick) of the MGs from offspring of homozygous MMTV-Cre and 
Rosa26STOPloxPLacZ mice (expression of β-galactosidase is possible only after Cre-
mediated deletion of a stop codon flanked by loxP sites; Jackson Laboratory) with X-
gal solution as described by Bonnerot et al. (29). Sections were counterstained with 
Nuclear Fast Red.  Controls were MGs from Rosa26STOPloxPLacZ mice. To further 
assess organ-specificity of the MMTV-Cre-mediated Fn knockout in MGs, DNA was 
extracted from lung (Lu), heart (He), kidney (Ki), mammary gland (MG), salivary 
gland (SG), uterus (Ut) and liver (Li) of FnMEp-/- mice. PCR was performed with the 
primers designed from regions flanking the Fn1 lox-P sites. Fn deletion results in a 
320 bp band, while floxed Fn1 revealed a 1,200 bp band. 
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Mammary Gland Whole Mount Preparation, Staining, and Analyses 
 The left 4th inguinal mammary fat pad (MFP) was excised essentially as 
described by Tiran and Elson (30). In brief, excised MFPs were spread onto glass 
slides and fixed with Tellyesniczky’s fixative overnight. MFPs were then soaked in 
three changes of 100% acetone each for 6h, followed by 2h-treatments with each 
100%, 95% and 70% ethanol, and stained with 0.2% carmine red overnight. After 
rinsing in water, MFPs were dehydrated sequentially in 50%, 70%, 95%, and 100% 
ethanol each for 2h, cleared with methyl salicylate overnight and examined under a 
dissecting microscope. MG whole mounts were evaluated as follows: (i) Extent of 
ductal outgrowth (maximal outgrowth beyond MFP lymph node measured in 
millimeters; (ii) number of ductal branch points per unit area of MFP; and (iii) number 
of terminal end buds (TEBs) in MGs from virgin mice (virgin mice 5- and 16-weeks 
old) as described by Shen et al. (23); and (iv) size and number of alveolar lobules from 
MGs of pregnant and lactating mice. A minimum of 7 mice per each age-category and 
genotype were analyzed. 
 
Histologic and Morphometric Techniques 
 The right 4th inguinal MFP was excised as described above, spread onto glass 
slides and fixed with phosphate-buffered 4% paraformaldehyde overnight at 4°C. 
MFPs were then subjected to routine paraffin-embedding, and 4-µm thick, planar 
sections stained with hematoxylin & eosin (H.&E.).  Sections were evaluated as 
follows: (i) assessment of the tissue architecture and branching pattern; and (ii) 
estimation of the volume density (VMG) of the glandular structures occupying the MFP 
as described by Weibel et al. (31) and Pauli et al. (32), using computer-enlarged 
photographs from entire MFP sections and superimposed test lattices of 1-cm2 
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subunits: VMG=Pi (number of line intersection points falling on MG components) / PT 
(total number of intersection points falling on MG components + MFP stroma) (32). A 
minimum of 7 mice per each age-category and genotype were analyzed. 
 
Immunohistochemistry 
 Paraformaldehyde-fixed sections from the right 4th inguinal MFP mounted on 
poly-L-lysine coated glass slides were used for immunohistochemical analyzes. Prior 
to staining with primary antibody (mouse anti-Fn monoclonal antibody directed 
against the EDA domain of human Fn1: 1:50; overnight; 4°C) (Santa Cruz 
Biotechnology), 5-µm thick, deparaffinized sections were treated sequentially with 1% 
pepsin (Sigma) in 10 mM HCl (pH 2.0; 30 min; 37°C) for antigen unmasking, M.O.M. 
Ig blocking reagent (M.O.M. Immunodetection kit; Vector Laboratories, Burlingame, 
CA) for blocking endogenous immunoglobulin, and normal horse serum (R.T.U. 
Vectastain® Universal Elite ABC kit; Vector Laboratories) for blocking unspecific 
binding of the secondary antibody. Detection of bound primary antibody was by 
biotinylated horse anti-mouse secondary antibody, ready-to-use, stabilized ABC 
reagent (R.T.U. Vectastain® Universal Elite ABC kit) and the peroxidase substrate 3-
amino-9-ethyl carbozole (AEC; Invitrogen, Carlsbad, CA). Sections were washed 
vigorously with PBS between each step of this procedure and counterstained with 
hematoxylin (5 seconds; room temperature). Control section were stained normal 
mouse IgG instead of primary antibody. 
 
Assessment of MEp Proliferative and Apoptotic Rates 
 The MEp proliferative rate was estimated by BrdU assay. In brief, mice were 
injected intraperitoneally with 0.1 ml/10 gm body weight of BrdU solution 
(Invitrogen) 2 hours prior to sacrifice. BrdU-positive cells were detected by 
immunohistochemistry using anti-BrdU antibody (1:150 dilution; 1.5 h; 37°C) 
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(Invitrogen) essentially as described above. The proliferative rate was expressed as the 
percent BrdU-positive cells of the total number of MEps counted (~1,000 cells/MG 
counted). 
 The MEp apoptotic rate was determined by the cleaved caspase 3 
immunohistoichemical assay (23). The anti-cleaved caspase 3 antibody was from BD 
Biosciences (San Jose, CA) and was used at a dilution of 1:150 as described above. 
The percent cleaved caspase 3-positive cells of the total number of MEps (~1,000 cell 
counted) was used as an expression of the MEp-apoptotic rate.  
 
Biochemical Analyses 
 To assess the role of the downstream Fn-signaling partners in the lobulo-
alveolar differentiation of the MG, MG were homogenized in lysis buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM benzamidine 
chloride, 1 mM PMSF, 2 µg/ml leupeptin, 0.27 TIU/ml aprotinin, 0.1 mM sodium 
vanadate, and 1% Triton X-100) and incubated for 1h at 4°C (33). Total cell lysates 
were subjected to SDS-PAGE (~20-50µg protein) and Western blotting (33), using 
anti-Fn (Sigma), anti-ItgB1 (Sana Cruz Biotechnology), anti-focal adhesion kinase 
(FAK) (Biomol), anti-FAK(pY397) (Biomol), HRP-conjugated  donkey anti-rabbit or 
goat anti-mouse secondary antibodies and ECL for detection of bound antibody as 
described (33).  
 
RESULTS 
 
MMTV-Cre Mediated Recombination 
Mice used in this study had the following genotypes:  (i) Fnfl+/+, (ii) MMTV-
Cre+Fnfl+/– (phenotype: FnMEp+/–) and (iii) MMTV-Cre+Fnfl+/+ (phenotype: FnMEp–/–). 
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These genotypes were identified by PCR using tail-derived genomic DNA and primer 
sets that flanked the floxed sites of the Fn gene as described in Material and Methods. 
The same set of primers was also used to PCR-probe DNA isolated from various 
organs including lung, heart, kidney, liver, uterus, mammary gland, and salivary gland 
in order to examine which organs exhibited Cre recombinase activity.  In MMTV-
Cre+Fnfl+/+ mice only mammary gland and salivary gland exhibited strong Cre activity 
as visualized by deletion of the floxed Fn-segment (320bp band) in these organs (Fig 
A.1A). In contrast, heterozygous MMTV-Cre+Fnfl+/– mice exhibited both Fn-species 
(i.e., deleted [320bp] and undeleted [1.2kb] floxed-Fn) and Fnfl+/+ mice revealed only 
undeleted, floxed Fn as expected (data not shown). To further assess the selectivity of 
Cre recombinase activity and expression in MEp, we stained frozen sections from the 
mammary gland of MMTV-Cre+- Rosa26STOPloxPLacZ and Rosa26STOPloxPLacZ 
(control) mice with X-gal. X-gal staining was only observed in the mammary 
epithelium from MMTV-Cre+- Rosa26STOPloxPLacZ mice, where Cre recombinase 
activity removed a floxed stop colon to allow expression of LacZ (Fig A.1B). No X-
gal staining was observed in non-epithelial tissues.  Age-matched, Cre-negative 
control mice revealed no X-gal staining of the mammary epithelium (Fig A.1C). To 
examine Fn protein expression we selected mammary gland from 15-day pregnant 
Fnfl+/+ and FnMEp–/– mice since at stage mammary glands of normal mice express 
relatively high levels of Fn (17) and since most of the MFP is occupied by glandular 
tissue thereby keeping the amount contributed by the stromal compartment at a 
minimum. As expected, Fnfl+/+ mice exhibit strong Fn expression, while Fn expression 
in FnMEp–/– mice varied from approximately 0 to approximately 40% (Fig A.1D). 
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Figure A.1: Conditional Knockout of Fn in Mammary Epithelia: (A) DNA was 
extracted from lung (Lu), heart (He), kidney (Ki), mammary gland (MG), salivary 
gland (SG), uterus (Ut) and liver (Li) of MMTV-Cre+Fnfl+/+ mice. PCR was performed 
with the primers designed from the regions flanking the Fn loxP sites. Fn deletion 
results in a 320bp band, while floxed Fn in a 1200bp band. (B) Frozen section from 
the MG of a 16-week old MMTV-Cre/Rosa26STOPloxPLacZ mouse stained with X-
Gal solution (Fermentas) and counterstained with Fast Red. Notice the select 
expression of Cre-recombinase activity in MEp, but not surrounding stromal cells (C) 
X-Gal staining of a frozen section from the mammary gland of a 16-week old 
Rosa26STOPloxPLacZ control mouse. X-Gal staining is negative. (D) Fn protein 
expression in Fnfl+/+ and FnMEp–/–mice. 
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Analyses of MFP Whole Mounts 
Carmine red-stained MFPs from each age-group and genotypes of mice were 
analyzed qualitatively and quantitatively. At five weeks of age, mice with MMTV-
Cre-mediated deletion of floxed Fn [FnMEp–/–] exhibited a significant retardation in 
ductal outgrowth of the MG relative to heterozygous FnMEp+/– and Fnfl+/+ mice (Figs 
A.2 and A.3A&B). Also decreased were the number of ductal branch points and the 
number of terminal end buds (TEBs) relative to the two control groups [FnMEp+/–; 
Fnfl+/+] (Fig A.3C&D). At 16 weeks of age, ductal outgrowth and number of branch 
points in FnMEp–/– mice were still decreased, but statistically indifferent from those of 
control FnMEp+/– and Fnfl+/+ mice (Fig A.3B&C). The most dramatic changes in MG 
postnatal development were observed at day 15 of pregnancy. The MG of FnMEp–/– 
mice exhibited normal ductal development and branching extending from the nipple to 
the terminal ductules (Fig A.2), but lobulo-alveolar differentiation, typically observed 
at this stage of pregnancy in normal mice, was totally missing (Fig A.2). Together, 
these data show that Fn deletion in MEp caused a minor retardation in ductal 
outgrowth and number of branch points in adolescent FnMEp–/– mice relative to the two 
age-matched control groups [FnMEp+/–; Fnfl+/+]. However, at 16 weeks of age MG 
ductal outgrowth and branching in FnMEp–/– mice had caught-up to those in age-
matched control mice (Fig A.3 B&C), suggesting that Fn-deletion might have slowed 
the rate of MEp proliferation. 
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Figure A.2: Mammary Gland Whole Mounts from Fnfl+/+ and FnMEp–/– mice: At 5 
weeks, there is a noticeable retardation in the ductal outgrowth, decreased branching, 
and decreased occupancy of the MFP with glandular elements in FnMEp–/– relative to 
Fnfl+/+ mice. At 16 weeks (virgin mice; v16w), ductal outgrowth and branching are 
almost identical and there is only a minor decrease in mammary fat pad (MFP) 
occupancy in FnMEp–/– relative to Fnfl+/+ mice. In pregnant mice at day 15, there is a 
total lack in lobulo-alveolar differentiation in FnMEp–/– mice (see higher magnification) 
and a normal lobulo-alveolar differentiation in Fnfl+/+ mice (see higher magnification). 
There is a more or less identical density and branching pattern of MG ducts that 
extend to terminal ductules in Fnfl+/+ and FnMEp–/– mice. Bar: 1mm.  
No noticeable differences were observed between heterozygous FnMEp+/– and Fnfl+/+  
and wild-type FVB mice (data not shown). 
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Figure A.3: Quantitative Aspects of the Effects of Fn-knockout on MG postnatal 
development:  MG whole mounts were used to measure outgrowth of ductal branches 
beyond the fat pad lymph node (A & B) and to count the number of branch points of 
outgrowing ducts (C) in 5- and 16-week-old, Fnfl+/+, heterozygous FnMEp+/-, and 
homozygous FnMep-/- virgin mice. Also counted was the number of terminal end buds 
(TEBs) (D) in 5-week old mice from the three groups of mice. Notice retarded ductal 
outgrowth and decreased numbers of branch points and TEBs in FnMep-/- mice, relative 
to FnMEp+/- and Fnfl+/+ mice at 5 weeks, but no significant differences at 16 weeks. 
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Histological Analyses 
Histological examination of planar sections prepared from mammary glands of 
mice of the same groups complemented our findings from MG whole mounts. At 5 
weeks of age, there was a slightly decreased number of ductal cross-sections in FnMEp–
/– mice relative to Fnfl+/+ mice (Fig A.4 & Fig A.5A). However, this did not result in a 
statistically significant difference in the MG/MFP volume percent. Similar 
observations were made in 16-week old virgin mice. Glandular cross-sections were 
more frequent and there was a more pronounced branching in Fnfl+/+ relative to FnMEp–
/– mice (Fig A.4 & Fig A.5B). Again, dramatic differences were only observed in 15-
day pregnant females. There was normal lobulo-alveolar differentiation in Fnfl+/+ mice 
versus a rudimentary to a total lack of lobulo-alveolar differentiation in FnMEp–/– mice 
(Fig A.4 & Fig A.5D&E). This observation was reflective of a significant decrease in 
MG/MFP volume percent in the latter group of mice (Fig A.5 C-E). No statistical 
differences were observed between Fnfl+/+ and FnMEp+/– mice. To examine whether the 
difference in the MG/MFP volume percentages between Fnfl+/+ and FnMEp–/– mice was 
due to changes in the rates of proliferation and apoptosis of mammary epithelial cells 
in FnMEp–/– mice, we performed a BrdU incorporation and cleaved caspase-3 assays. 
Results show a significant decrease in the rate of proliferation of MEps in FnMEp–/–
mice relative to Fnfl+/+ mice (Fig A.6), but no significant differences in the rate of 
apoptosis (data not shown).  
 
Immunohistochemical Analyses 
Anti-Fn staining of mammary gland planar sections from 5 and 16-week old 
virgin mice of the three animal groups yielded no reportable differences. However, in 
15-day pregnant mice, there were intriguing differences between Fnfl+/+ and FnMEp–/– 
mice. At low magnification, there was little or no Fn-staining in MG sections from  
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Figure A.4: Horizontal Section of Mammary Glands from Fnfl+/+ and FnMEp–/– 
Mice Stained with H.&E.: At 5 weeks, there is a decreased number of ductal cross-
sections in FnMEp–/– mice relative to their heterozygous counterparts. At 16 weeks 
(virgin 16w), MGs from FnMEp–/– mice show ductal cross-sections (D) and branching 
ductules (d) and no alveolar development, while MGs from Fnfl+/+ mice exhibit a 
higher density of ductal cross-sections and indications of alveolar differentiation (a). 
At 15 days of pregnancy, MGs of FnMEp–/– exhibit good ductal branching, ducts and 
ductules are collapsed and contain no milk, lobulo-alveolar differentiation is lacking. 
Newborn pups die within 2 days following birth. In contrast, Fnfl+/+ mice show 
extensive lobulo-alveolar differentiation  and ducts (D) and ductules (d) are filled with 
milk. Pups develop normally. Images are depicted at identical magnifications. 
 
 
 
 
 
 
 
 
162 
  
 
 
 
 
 
163 
  
 
 
 
 
Figure A.5: Mammary Gland Volume Density of the Mammary Fat Pad: Five 
micron thick paraffin sections were prepared from the mammary gland of 5 adolescent 
5-week old mice (A), 5 adult virgin 16-week old mice (B), and 5 15-day pregnant 
mice (C) with the phenotypes Fnfl+/+, FnMEp+/- , and FnMep-/-. The MG volume density 
of the mammary fat pad was determined by standard morphometric techniques, using 
computer-enlarged photographs from entire MFP sections and superimposed test 
lattices of 1-cm2 subunits: VMG=Pi (number of line intersection points falling on MG 
components) divided by PT (total number of intersection points falling on MG 
components + MFP stroma) (150). Statistically significant differences in the volume 
density of MGs were only observed in 15-day pregnant mice, where the MG volume 
density in FnMep-/-  was dramatically decreased relative to the MG volume densities in 
Fnfl+/+ and FnMEp+/-  mice (C). This difference in MG volume densities is readily seen 
in H.&E.-stained sections from Fnfl+/+(D) and FnMEp+/-(E) mice. D & E Insets: Fn 
protein expression; actin loading control. 
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Figure A.6: Cell Proliferation Assay: BrdU-staining of mammary gland section from 
a 10-day pregnant Fnfl+/+ control mouse (A) and a 10-day pregnant FnMep-/-  mouse (B), 
both injected 2h prior to euthanasia with 100µg BrdU/gm of BW. There is a 
significant decrease in the number of BrdU-positive MEps in FnMep-/-  mice relative to 
control Fnfl+/+ mice (counts are from 200 MEps in each of 3 mice per category) (C). 
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FnMEp–/–  mice, showing only rudimentary lobulo-alveolar differentiation (Fig A.7A), 
while MG sections from  Fnfl+/+ mice exhibited a haze of Fn staining around small 
ductules and newly formed alveoli (Fig A.7B). Staining was particularly strong around 
small blood vessels. At high magnification at the tip of sprouting ductules, epithelial 
cells lost their cuboidal shape and assumed a spindle- mesenchymal-like shape as they 
penetrated surrounding connective tissue shape in a manner reminiscent of epithelial-
mesenchymal transition of invading cancer cells (Fig A.7C, arrows). At the same time, 
the cell body of spindle-shaped epithelial cells stained positive for Fn. Such staining 
was especially prominent at the tip of the invading cell. In other areas of lobulo-
alveolar differentiation epithelial cells separating from the tubular confines of alveoli 
and sprouting into neighboring tissues stain positively for Fn (Fig A.7D&E). These 
processes are reminiscent of budding alveoli and are accompanied by strong Fn 
expression. Also noticeable is a strong Fn staining reaction around newly formed 
blood vessels of the lobulo-alveolar compartment. Such staining was absent around 
mature blood vessels outside the lobule.  
 
Neovascularization of Mammary Gland Lobules  
Lobulo-alveolar differentiation in 15-day pregnant Fnfl+/+ mice was associated with a 
flurry of newly formed blood vessels that was associated with Fn staining at their 
periphery (Fig A.8; arrows). In contrast, age-matched FnMEp–/– mice of the same stage 
of pregnancy exhibited rudimentary alveolar differentiation with few blood vessels 
and little or no Fn-staining (Fig A.7A). To examine whether the increased 
neovascularization was associated with increased expression of vascular endothelial 
cell growth factor (Vegf) expression, we extracted total RNA from Fnfl+/+ and FnMEp–/– 
mice and determined Vegf expression levels relative to the housekeeping gene Gapdh, 
using RT-PCR. Data show a more than 8-fold decrease in Vegf expression in  
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Figure A.7: MG Immunohistochemistry: Five µm-thick sections from MGs of 10-
day pregnant FnMep-/-  (A) and Fnfl+/+(B-E) mice were stained with anti-Fn polyclonal 
Ab. At low magnification (A & B), there is little or no Fn-staining in MG sections 
from FnMep-/-  mice showing only rudimentary lobulo-aveolar differentiation (A), while 
MG sections from Fnfl+/+mice exhibit a haze of Fn-positive staining around small ducts 
and particularly within areas of early lobulo-alveolar differentiation that is especially 
prominent around small blood vessels (B). At higher magnification of MG sections 
from Fnfl+/+ mice (C-E), there are Fn-positive cells that have undergone epithelial-
mesenchymal transition at the tip of a sprouting terminal ductule (arrows, C), Fn-
positive epithelial cells “dropping out” from the alveolar lining (arrows D) and 
forming new alveolar structures (arrows E). 
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mammary glands from 15-day pregnant FnMEp–/– mice over Fnfl+/+ mice Fnfl+/+ mice 
(Fig A.8). 
 
Fn, Integrin β1, and Focal Adhesion Kinase - Mediators of Lobulo-Alveolar 
Morphogenesis? 
Conditional knockout of either Fn, integrinβ1 (Itgb1) (35,36), or focal 
adhesion kinase (FAK) (37) in mammary epithelium appeared to have a similar effect 
on mammary gland postnatal morphogenesis. They all caused failure of lobulo-
alveolar differentiation during pregnancy. To test whether Itgb1 and FAK might act 
downstream of Fn, we examined expression of these proteins and in the case of FAK, 
the activation status, in the mammary glands of Fnfl+/+ and FnMEp–/– mice. Indeed, 
knockout of Fn triggered a decrease in Itgb1 expression and autophosphorylation of 
FAK, but no decrease in FAK protein expression (Fig A.9). 
 
DISCUSSION 
 
Fibronectin has been introduced as a multi-domain glycoprotein that regulates 
a variety of cellular functions including differentiation, proliferation, apoptosis, 
migration (1-3). As such it is involved in embryologic and postnatal development (14-
16), tissue homeostasis, wound healing, angiogenesis, and cancer (1-10). Here, we 
have analyzed the effects of conditional knockout of Fn in mammary epithelial cells 
on postnatal development of the mammary gland. Studies of adolescent (5 weeks) and 
adult virgin (16 weeks) mice of the three phenotypes Fnfl+/+, FnMEp+/–, and FnMEp–/– 
yielded quantitative differences in the expansion and differentiation of the ductal tree 
within the mammary fat pad between groups, but no significant differences in the 
branching pattern. Noteworthy are statistically decreased distances of branch 
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Figure A.8: Neovascularization of the Lobulo-Alveolar Compartment in Fnfl+/+ 
Mice: Histologic section of the lobulo-alveolar compartment of a 15-day pregnant 
Fnfl+/+ mouse exhibits a high vascular density (arrows), that is absent in 15-day 
pregnant FnMep-/- mice (see Fig. A.7A). This result is mimicked by a strong message 
for Vegf in MGs from Fnfl+/+ mice and a very weak Vegf message in MGs from FnMep-
/-   mice. 
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Figure A.9: Fn-Signaling via Itgb1 and FAK during MG Development in 15-day 
Pregnant Fnfl+/+, but not FnMEp–/– Mice: MGs (4th; inguinal) were extracted in lysis 
buffer and subjected to Western blotting with anti-Fn, anti-Itgb1, anti-FAK, and anti-
FAK(pY397). Fnfl+/+ MGs exhibit strong Fn, Itgb1, and FAK(pY397) expression, 
while FnMep-/-  MGs fail to activate FAK and have somewhat reduced Itgb1 expression. 
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outgrowth, numbers of branch points, and number of TEBs in 5- week old FnMEp–/– 
mice. These differences were still present in 16-week old FnMEp–/– mice, but were less 
pronounced and statistically not significant due to variability between samples 
asvisualized by large standard deviations in our statistical analyses, likely due to the 
mosaic Cre expression (34). Dramatic, statistically sound differences were observed 
only in pregnant mice, where the mammary glands of FnMEp–/– mice exhibited severe 
deficiencies in the typical lobulo-alveolar differentiation observed in the two control 
groups, i.e., Fnfl+/+ and FnMEp+/– mice (see Fig A.5). The degree of lobulo-alveolar 
impairment in FnMEp–/– mice ranged from severe hypoplasia to aplasia and was closely 
associated with the amount of Fn protein recovered from these glands. Failure of 
lobulo-alveolar differentiation resulted in lack of milk production and early death of 
newborn pups (<2days).  
Our data mimic to a large extent those reported for mice with the conditional 
knockout of the β1 integrin (Itgb1) (35,36) and  focal adhesion kinase (FAK) (37) in 
the mammary epithelium. Fn-knockout in mammary epithelium, like Itgb1- (35,36) 
and FAK-knockout (37), did not affect the pattern of ductal outgrowth and branching, 
albeit both were slowed down somewhat in FnMEp–/– and FAKMEp–/– mice. In pregnant 
mice, deletion of Fn, Itgb1, and FAK left only a skeleton of ducts and ductules (Fig 
A.2) with lack of lobulo-alveolar differentiation and ensuing inability of females to 
produce milk and nurse their pups (35-37). These data suggest that Fn may operate 
proximal of Itgb1 and FAK (38). In support of this notion Fn deletion was followed by 
significant decreases in Itgb1 expression and autophosphorylation of FAK, while FAK 
protein expression remained constant. Disruption of Fn-Itgb1-FAK interactions and 
associated malformation of focal adhesions (35) may have accounted for the observed 
decreased rate of proliferation that was most prominent in 16-week old virgin and 15-
day pregnant FnMEp–/– mice. Such impaired proliferation has also been noticed in 
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Itgb1- and FAK-knockouts in the mammary epithelium as well as in mammary glands 
of mice that expressed a dominant-negative chimeric form of Itgb1 (39). Moreover, 
consistent with our in vivo observation, mammary epithelial cells isolated from   
Itgb1MEp–/– mice expressed decreased levels of tyrosine phosphorylation at residue 397 
of FAK relative to mammary epithelial cells from Itgb1-floxed mice (35).  
In the mammary gland of Fn MEp–/– mice branching initiation, branch 
outgrowth, elongation and ramification seem to occur independent of Fn, albeit 
epithelial-mesenchymal transition (EMT), which involves expression of Fn, has been 
implicated to be responsible for the expansion (invasion) of the ductal tree within the 
mammary fat pad (40). However, our morphologic studies are more indicative of 
“cohort-type” of invasion of ducts into the mammary fat pad, rather than a 
“mesenchymal-type” of invasion (41) that involves individual spindle-shape cells of 
files of cells to penetrate MFP tissue. In contrast, at sites of alveologenesis epithelial 
cells arising from terminal ductules and primary alveolar buds seem to separate 
themselves from the epithelial lining and enter the mammary fat pad. These cells are 
spindly (mesenchymal) in shape and are strongly Fn positive and appear highly motile 
(42). The driving forces behind these processes are not well established, but could well 
be mediated by Fn itself, which has been shown to exert an EMT promoting effect 
(43). Differentiation of the newly created lobuloalveolar compartment could then be 
achieved by Jak2/Stat5a-signaling, reversing EMT and promoting differentiation of 
epithelial cells as shown by accompanying increased expression of E-cadherin, zonula 
occludens-1 and cytokeratins 8 and 18 (44). 
Lobulo-alveolar differentiation in the mammary gland of Fnfl+/+ mice is 
associated with an elaborate neovascularization process, as shown by the formation of 
vascular honeycombs around the alveolar structures (45) and high levels of Vegf 
expression. Such neovascularization is missing in FnMEp–/– mice and, correspondingly, 
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Vegf expression is low. This result may be in response to extensive, new, lobulo-
alveolar growth in Fnfl+/+ mice and lack thereof in and FnMEp–/– mice. However, several 
studies suggest a more direct involvement of Fn in Neovascularization. For example, 
(i) rat coronary neovascularization during prenatal and early postnatal development 
was preceded by the deposition of Fn suggesting that Fn may provide a primary 
scaffolding for the migration of primordial endothelial cells/angioblasts (46); (ii) 
Retinal vasculogenesis follows the spread of astrocytes into the nerve fiber layer of the 
retina and the deposition of Fn in the zone of vasculogenesis (47); (iii) Proliferative 
diabetic retinopathy, a condition which entails proliferation of microvascular 
endothelial cells and retinal neovascularization is associated with upregulation of Fn 
extra domain B (EDB) (48); (iv) Exposure of endothelial cells to EDB+-Fn or EDB-
polypeptide significantly increased Vegf expression and promotes endothelial 
proliferation and tube formation in vivo (49). 
In summary, we have present novel evidence of the role of Fn in postnatal 
mammary gland morphogenesis. Conditional knockout of Fn in mammary epithelium 
leads to severe lobulo-alveolar hypoplasia/aplasia. Concomitant downregulation of 
Itgb1 and decrease autophosphorylation of FAK suggest that this pathology is 
mediated, at least in part, by disruption of Fn/Itgb1/FAK signaling pathway. This 
notion is supported by the fact that conditional knockouts of Itgb1 and FAK generate 
the same pathology as Fn-deletion (35-37). Moreover, a more that 6-fold 
downregulation of Vegf and significantly impaired neovascularization in FnMEp–/– 
mice further compromised lobulo-alveolar differentiation. 
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